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The goal of this project is to find a molecular probe for HPV variant 16 protein E6. This 
goal is accomplished using a combination of Virtual Ligand Screening (VLS) and experimental 
ligand binding assays.    
Protein E6 is a protein that is expressed in all individuals with the human papillomavirus 
(HPV) virus. A number of HPV 16 protein E6 genetic variants have been associated with 
increased risk for cervical cancer. Currently, there is no fast and reliable method for testing for 
the presence of these high-risk protein variants. We want to develop a method that is both fast 
and reliable for detecting the presence of this protein using molecular probes. These molecular 
probes could potentially be used for optical or PET diagnostic imaging, for risk-assessment and 
to guide early intervention. 
Using virtual ligand screening, we have identified a number of molecular probe 
candidates with affinity for the binding site of prototype E6. This affinity is assessed using 
binding energy scores. Compounds possessing favorable calculated binding energy scores and 
other desirable molecular properties are identified as potential molecular probes. Selected 
candidates include: O-succinyl-L-homoserine (-46 kcal/mol), paclitaxel (-70 kcal/mol), and 3-
Amino-5-fluorobenzo [E] [1,2,4] Triazine 1, 4 dioxide (-47kcal/mol), for 3-Chloro-2-(2-[(3-oxo-
2-Benzfuran-1 (3H)-Yliden] methyl) Hydrazino)-5-(Trifluoromethyl) Pyridinum Acetate (-
68.33kcal/mol), 3-Chloro-2-(3-[1-(Phenyl sulfonyl)-(H-pyrazol-3-YL] Phenoxy)-5-
(Trifluoromethyl) Pyridine (-66.12kcal/mol), and N-(2,4-dinitrophenyl)-L-arginine ) (-
78.58kcal/mol).  
We have performed experimental ligand-binding assays of the potential molecular probes 
against purified prototype protein E6. Both intrinsic tryptophan fluorescence and fluorescence 
 
II 
polarization assays have been performed. One of our compounds 3-Amino-5-fluorobenzo [E] 
[1,2,4] Triazine 1, 4 dioxide (AFTD) was shown to have affinity for our target protein (EC50 
6M). Due to its intrinsic fluorescence and the presence of a fluorine atom, this molecule could 
potentially be used for either PET or optical imaging modalities. Cell based assays have also 
been conducted to further characterize AFTD's potential as an in vivo imaging probe. Results 
indicate that AFTD is cytotoxic at 25M, although it appears to be cell permeable. Further 
experiments need to be conducted to assess its potential use as in-vivo imaging probe. An 
alternative use for this molecule as a probe in biochemical assay tracking E6 protein-protein 
interactions is suggested. This is demonstrated using a monoclonal antibody (6F4) that is specific 
to HPV16 E6. These results set the stage for future work to further characterize this potential 
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Human Papillomavirus (HPV) is a double stranded DNA virus
1
. To date this virus has 
more than 150 types known. Some types are considered high risk and some low risk with regards 
to likelihood of cancer development
3
. High risk HPVs can cause cancerous lesions, whereas low 
risk HPVs is associated with benign lesions
4
.  This relationship was first described by Dr Harold 
zurHausen and collaborators during the 1980s. This was the first time that HPV DNA was 
isolated and discovered in a cervical tumor biopsy
5
. It is estimated that about 99.7% of cervical 
cancer cases are HPV positive
6
. The majority of these cases are shown to be HPV16 (50-70%)
7
. 
More recent numbers have indicated a more exact number of 54.4% of cervical cancer cases are 
linked to HPV16
8
. HPV not only has a link to cervical cancer but it is estimated that 90% of 
anogenital cancers are HPV positive
8-9




1.2.PROTEINS EXPRESSED IN THE HPV GENOME 
Long control regions (LCR) in the HPV genome encode six proteins (E1, E2, E4, E5, E6, 
E7, L1 and L2), which are expressed either early or late in the infection. L1 and L2 are expressed 
later in the infection and are found within the upper layers of the infected epithelium
10
. The early 
proteins (E1, E2, E4, E5, E6, and E7) are found in the lower to mid epithelial layers
11
. E1 and E2 
are responsible for the initiation of viral replication and control gene expression
11
. E4 and E5 
proteins aid in genome amplification
11






E7 is known for its interaction with retinoblastoma protein (pRb), which leads to the 
release of transcription factor E2F which causes entry into S phase of the cell cycle
13
. This will 
lead to increased cell proliferation
13
. E6 plays a critical role in cell immortalization by degrading 
tumor suppressing protein p53
14
.   
1.3.PROTEIN E6 PROTEIN INTERACTIONS LEADING TO CELL 
IMMORTALIZATION 
Protein E6 is known as an oncoprotein due to its role in cancer development. E6 is shown 
to lead to the ubiquitination of p53
15
. The process of ubiquitination requires a protein ligase to 
transfer the high-energy thioester bond to the protein in order to transfer ubiquitin
16
. This process 
is facilitated through the binding of E6 and E6 associated protein (E6AP) 
17
. This complex will 
work as an E3 ligase and will transfer the thioester bond to protein p53 leading to its 
ubiquitination (Figure 1)
17
. The presence of ubiquitin will signal the proteosomes to come and 
degrade the protein
16
. The presence of E6 can also supress p53 function in an E6AP independent 
manner. This is through its interaction with p300/CBP complex
18
. Protein p53 is a tumor 
suppressor, important in the prevention of cancer. It functions as the guardian of the cell
19
. 
Protein p53 keeps the cell cycle regulated and it is involved in DNA repair
19
. The levels of p53 
are regulated in the cell, and generally, p53 has a short half-life
20
. Levels of p53 are also shown 
to increase upon any detected DNA damage, which can lead to mutations
19
. p53 will activate cell 
cycle arrest in these situation leading to potential apoptosis
19
. Low levels of p53 have been 
documented in almost all carcinomas
19
. This is not a surprise as destruction of p53 increases 
cancer susceptibility.  In the absence of p53, cell division is no longer properly controlled and 
DNA repair mechanisms are depleted
19






Figure 1: Ubiquitination of p53 mediated through the presence of E6. Flow chart shows the 
process leading the degradation of p53 in a series of steps. Certain variants of E6 bind to E6AP 
in such a way to allow this process to occur. The majority of these E6 variants are expressed in 
HPV type 16.  
 
E6 is also shown to interact with other proteins such as MAGI-1
21





. These PDZ contain domain-containing proteins are responsible for cell 
signalling and cell polarity, leading to cellular transformation to a malignant phenotype
22
. The 
presence of E6 also upregulates hTERT expression, which leads to E6 induced telomerase 
activity
24
.  This increased telomerase activity will protect chromosomes from damage during cell 
division
25
.     
1.4.SPECIFIC E6 PROTEIN VARIANTS LEAD TO INCREASED CANCER 
SUSCEPTIBILITY 
Specific changes from the prototype E6 have been shown to increase the risk for the 
development of cancer
7
. Some high-risk E6 variants include: Q14H/H78Y/L83V and 
R10G/L83V 
7
.  Although all E6 proteins bind to E6AP it is believed that certain mutants bind in 
such a way to facilitate the interaction with p53
26
. Much of these variants of E6 are associated 
E6 E6 + E6AP   Ubiquitin ligase 
Transfer of 
thioester bond of 








. In addition,  recent studies have indicated that these high-risk variants of  E6 alone 
can lead to cell immortalization and increased susceptibility to cancer development
27
. This 
makes E6 an ideal biomarker for high-risk HPV.  This creates an excellent opportunity to find a 
molecular probe that is specific for HPV16 E6, in particular those variants associated with cancer 
development. Prior to looking at high-risk variants, methods will have to be employed on the 
prototype in order to obtain proof of concept. An E6-specific molecular probe could serve two 
purposes: it could be used as a tool for diagnostic imaging for early intervention, or it could be 
used as a molecular probe for biochemical assays involving E6 protein interactions.  
1.5.THE PROCESS OF DEVELOPING A MOLECULAR PROBE 
Molecular probes aid in the visualization, characterization, and measurement of 
biological processes
28
. A molecular probe can be defined as an agent that has the ability to 
characterize and quantify biological functions
29
. Molecular probes can be target specific or non- 
specific
30
. A specific probe is a probe that only binds to one particular biomarker
30
. Non-specific 
probes do not bind to any specific target or have any biochemical activity in-vivo
30
.  Instead, 
they make use of high capacity systems such as blood and kidneys to provide image contrast. 
Molecular imaging probes assist medical imaging techniques and may bind to a specific 
biomarker, usually a protein. Advantages associated with the use of molecular probes include 
improved prognosis and improved staging
31
. Improved staging is the ability to determine the 
stage of the specific disease. This leads to a more specific treatment regime. These advantages 
come from the probe’s ability to specifically identify the biomarker at an early stage of the 
disease
3
. In order to obtain a probe with such advantages many steps need to be taken. The 
characteristics required to develop a molecular imaging probe include: high binding affinity for 
 
5 
target, high specificity to target, high sensitivity, high contrast ratio, high stability in vivo, low 
immunogenicity and toxicity,  production and economic feasibility (Figure 2)
31
.   
 
Figure 2: Desired characteristics of molecular probe. A molecular probe candidate must be 
evaluated for these characteristics. If the molecule does not pass one of these requirements, 
modifications to its structure may be introduced or an entirely new molecule may have to be 
considered.  
 
In order to be marketed as a molecular probe, the compound must be shown to have high 
affinity for the target. This molecule must bind quickly to the target and be slow to unbind
31
. As 
it is to be used in diagnostic imaging it is critical that it accumulates in the target tissue. In order 
to acquire a well-defined image, non-specific binding must be avoided
31
. Additionally, off-target 
binding must be avoided in order to reduce false positive rates
31
. It is for these reasons that 
affinity and specificity are crucial in the process of molecular probe development. Once affinity 
and specificity have been assessed experimentally, the probe must be shown to have high 
sensitivity, meaning that a small amount of molecular probe is needed to produce an image
31
. 





. Upon showing its potential to produce a high quality images, the probe must be shown 
to be stable in vivo. Due to the large amount of enzymes present in an organism, a probe could be 
easily degraded once placed in vivo. If the probe is easily degraded then it is not of much use
31
. 
Once all requirements have been met the compound can then be used as a molecular probe.  
1.6.PROJECT AIMS AND SCOPE 
The goal of this project is to identify and characterize molecular probe(s) for prototype 
HPV16 E6. In searching for a molecular probe, the requirements discussed earlier will be taken 
into consideration (Figure 2). For the scope of this thesis and the time frame allotted, we believe 
that we can identify probe candidates computationally, and evaluate both affinity and specificity 
to HPV16 E6 experimentally. Initial affinity to HPV16 E6 C-terminus, will be evaluated using 
computer software. Databases will be developed that contain compounds that are suitable for use 
as a molecular probe. Once docked these compounds will be further evaluated in order to 
determine, which compounds are worth testing experimentally.  
Upon finding probe candidates, experimental ligand binding assays will take place in 
order to further validate the affinity to target HPV16 E6. Once affinity has been evaluated, the 




Figure 3: Specific aims associated to the identification and characterization of potential 
molecular probes for HPV16 E6.   
 
Successfully achieving these aims will provide proof of concept for the development of a 
molecular imaging probe that is specific to those variants of HPV16 E6 shown to increase cancer 
susceptibility (Figure 3). Such probes will enable a specific test for high-risk HPV, thus 
facilitating diagnostics and early intervention in HPV-associated cancers.  
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Chapter 2.Background and Significance 
 
2.1.CURRENT CLINICAL PROCEDURES 
Human Papillomavirus (HPV) and its association with various cancers has become a 
large concern within health care. HPV is now one of  the most common sexually transmitted 
disease
1
. HPV is divided into several types, with HPV 16 and 18 being the highest risk for cancer 
development
2
. It is estimated that 68% of cervical cancer cases have HPV16 of HPV18 
genotype
3
. Due to this association specific screening methods for these high-risk HPV types need 
to be employed. Current screening methods, such as pap smears and cytological screening, have 
resulted in decreased incidence of invasive cervical cancer
4
. However, HPV remains a major 
burden on health care systems around the world
4
.  
Current burdens are over or under treatment of women with HPV infection
4
. This is due 
in large part to the lack of specificity of current screening methods
4
. The non-specific nature of 
screening leads to over/under treatment
4
. This issue could be quickly fixed with the use of a 
specific biomarker to properly evaluate the high-risk nature of the virus in a clinical setting. This 
biomarker could potentially reduce much of the current burden to the health care community. 
Current methods used in HPV detection include: 1) Woman with cytological 
abnormalities are brought in for additional screening  2) follow-up appointment for women with 
abnormal screening results 3) Cervical Intraepithelial Neoplasia (CIN)  is treated following a risk 
assessment; 4) HPV DNA testing is conducted, usually in combination with a Pap smear, to look 






Figure 4: Flow chart displaying the current clinical methods used in HPV detection. This is the 
rational used to detect HPV. Although these tests have alleviated some of the burdens that HPV 
creates, more specific tests are needed that consider the proteome as opposed to the genome.  
 
 In addition to these methods vaccines are available for HPV infection. There is a bivalent 
vaccine (type 16 and 18) and a quadrivalent (type 6, 11, 16, and 18)
6
. The vaccination against 
type 16 and 18 is thought to be able to lower the incidence of cervical cancer by more than two 
thirds
5
. Broad spectrum HPV vaccines are currently in development
5
. However, such vaccines 
are only available in certain parts of the world. This creates a need for highly automated, 
inexpensive screening method that can be used in all parts of the world.   
2.2.MOLECULAR GENOTYPING FOR HIGH RISK HPV TYPES 
The current methods for HPV detection rely heavily on molecular testing in order to 
identify the type of HPV present in the sample
5
. Current molecular methods for genotyping are 
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All of these assays have advantages and disadvantages associated with them. The biggest 
disadvantage of these methods is the lack of automation and the price
5
. In an attempt to 
overcome these disadvantage a study was conducted to genotype HPV infection using PCR from 
urine samples
7
. This paper was able to conclude by comparing results collected from cervical 
brush technique that HPV DNA can be accurately detected in urine samples
7
. These positive 
samples were then genotypes using RFLP typing
7
. This leads to another disadvantage of such 
molecular techniques. Genotyping a HPV infection, however important, is not always going to 
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be indicative of a cancer-causing HPV infection
5
. This is the advantage of using specific disease 
biomarkers such as HPV proteins E6 and E7
8
. These proteins are important in specific detection 
of HPV because certain variants of these proteins are associated with higher cancer development 
risk
8
. Even if molecular tests are done and the HPV infection is declared type 16 it does not 
mean that these oncoprotein variants are present. Research has shown that certain variants of E6 
can cause cell immortalization independent of E7
9
. This is due to E6s many interactions with 
other proteins including E6AP
10
.  Although all E6 proteins bind protein E6AP, certain variants 
are shown to interact in such a way to make this possible
10
. It is due to this complexity that 
specific testing for E6 needs to be implemented in current clinical practise.  
2.3.HPV16 E6 DETECTION  
Since E6 has been well defined as a biomarker for high-risk HPV
9
, a lot of work is being 
done in order to detect this protein. This is because of its major role in cell immortalization
9
. One 
way by which this protein can be detected is through the use of antibodies. However, since these 
antibodies are not cell permeable techniques such as High Intensity Focused Ultrasound (HIFU ) 
need to be employed for intercellular screening
11
. Studies conducted showed proof of concept 
using a combination of HIFU and microbubbles for the delivery of antibodies
11
. The antibodies 
used showed some therapeutic effects
11
. This suggests the potential of using antibodies for 
intercellular delivery using such methods. Antibodies can also be delivered inside the cell, using 
transfection reagents; however these reagents are toxic
11
. For this reason these reagents are only 
useful for in-vitro work. Being able to deliver an antibody to E6 can potentially be difficult as E6 
mainly resides in the nucleus
12
. Using a small organic molecule would be very beneficial for 
specific HPV16 E6 detection, even though small molecule interaction with proteins can be 
complex
13
. However, small organic molecules are more likely to be cell permeable then larger 
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molecules such as antibodies. These interactions are complex due to the high number of 
conformations that the molecule and protein can take
13
. As a result when selecting a small 
molecule as a potential ligand, conformational changes of the ligand need to be taken into 
account in order to make sure the binding event is properly scored.    
An additional monoclonal antibody method involving test strips is also available and 
recently described. This is an in vitro method for specific E6 detection and  has been shown to 
identify high risk HPV with 95% confidence
14
. Two monoclonal antibodies are used one specific 
for type 16 and the other for type 18 and 45
14
. This test gives great qualitative measure as it is 
shown to be able to detect high risk E6 variants.  
2.4.ANTIBODIES AGAINST E6 
 Monoclonal antibodies are available for the N-terminus of E6. Monoclonal Antibody 6F4 
was first developed by Giovane and colleagues
15
. It is a mouse monoclonal antibody specific to 
HPV16 E6. The epitope region was described by Mason and colleagues in 2003 is as following:   






EKQRHLDKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL   
Figure 5: Amino acid sequence of E6 prototype highlighting the epitope (yellow) recognized by 
antibody 6F4. This sequence was taken from GenBank (GenBank #AAA46939.1).  
 
2.5.SMALL ORGANIC MOLECULES THAT BIND SPECIFICALLY TO E6 
Little success has been made in the attempt to find a small organic molecule that binds 
specifically to E6. Some attempts have been made using zinc-finger ejecting molecules
17
.  A 
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pharmacophore model was developed in order to target the zinc-finger domain to inhibit the 
binding of E6AP
17
. The reason for targeting E6AP binding is that  E6 will not interact with p53 
unless bound to E6AP
17
.Through screening two databases, one from the National Cancer 
Institute (NCI) and that other from Sigma Aldrich
17
, 10 molecules were selected for testing and 
IC50 values were experimentally determined (Table 2)
17
.  
Table 2: Zinc-finger ejecting molecules tested experimentally. Two data bases were screened: 
one from the national cancer institute and the other was rare compounds available through Sigma 
Aldrich. A pharmacophore model was used in order to find compounds that would bind to a 
particular region in order to inhibit binding to E6AP. It was determined that none of the 
compounds generated an IC50 that was low enough to be used as a therapeutic drug.  
 
Compound name E6AP binding IC50 (µM) 
National Cancer Institute (NCI) 83143 29 
NCI 117907 29 
NCI 135098 22 
NCI 216029 12 
Sigma Aldrich (SA) s32701 52 
SA 207721 21 
SA r218634 27 
SA r225975 12 
SA r278319 17 
SA s204102 11 
 
Also when using controls for non-specific inhibition it was determined that the inhibition may 
have been non-specific
17
. Cell permeability tests were also conducted with NCI 117907, which 
was intrinsically fluorescent
17
. This compound showed little to no uptake at 100µM
17
. This result 
along with the non-specific nature of the binding interactions led to the conclusion that the 
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pharmacophore model failed. It is suggested that a better model could be made once a series of 
known compounds that bind to E6 are discovered
17
.  
To date there is no small organic molecule that is known to bind to HPV16 E6 with 
enough affinity to be marketed as a molecular probe. This makes our work extremely novel in 
the field of HPV detection.      
2.6.BIOCHEMICAL ASSAY FOR HPV16 E6 PROTEIN-PROTEIN 
INTERACTIONS 
 Currently, there is not a biochemical assay available for looking at HPV16 E6 protein-
protein interactions outside of the cell environment. Available assays tracking E6 protein-protein 
interactions take place in the cell environment. The most common is the Glutathione-S-
transferase (GST) pull-down assay. In this assay, a protein is fused to GST and expressed in E-
coli (bait protein) after which it is bound to glutathione (GSH)- coupled particles
18
. This will 
cause affinity purification of any proteins (prey) it comes into contact with
18
. This assay is 
deemed accurate
18
; however testing protein-protein interactions outside of the cell environment 
still serves an important purpose. Due to the massive amount of interactions inside the cell 
environment, testing protein-protein interactions outside of the cell environment can provide 
valuable information without confounding factors that would be present in the cell environment. 
Also, as the list of E6 protein-protein interactions continues to grow, having a biochemical assay 
to probe E6 interactions with other proteins will enable better understanding of HPV infection’s 
role in cancer.   
2.7.HPV PROTEIN E6 AND AVAILABLE STRUCTURES 
 Protein E6 is a small protein that is only composed of 151 amino acids (Figure 7)
19
. E6 
contains two distinct domain an N-terminus and a C-terminus domain, which are both 
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approximately 75 amino acids in length
19
. Both domains contain a zinc binding domain
17
. 
Finding a stable folded form of this protein has been a real challenge and has limited full 
understanding of the full-length E6 structure
19
. This small protein interacts with many proteins in 
the cell, with the most well-known partner being E6AP. The E6-E6AP complex is responsible 
for the ubiquitination of tumor suppressor p53
19
. The structure of E6 only contains one 





Figure 6: Amino acid sequence of E6 prototype highlighting tryptophan. This sequence was 
taken for GenBank (GenBank #AAA46939.1). E6 only contains one tryptophan making it 
suitable for intrinsic tryptophan fluorescence ligand binding experiments.  
 
Various experimentally determined structures for E6 are currently available through the PDB, 
which creates an excellent starting point for molecular docking.    
 At the beginning of this project, structural information for HPV16 E6 was limited as 
there was only one human HPV16 E6 structure available. This structure represented the C-
terminus of HPV16 E6 (PDB 2FK4)
19








This structure was solved using Nuclear Magnetic Resonance (NMR). This structure had 75 
amino acids (Figure 8)
19
 and was highly useful for our search for small organic molecules that 
bind to E6. In these structures some cysteine’s were mutated to serine in order to obtain better 







Figure 8: Amino acid sequence of E6 prototype highlighting the sequence corresponding to the 
structure with PDB code 2FK4 (red). This sequence was taken from GenBank (GenBank 
#AAA46939.1). The yellow represents mutations from the original sequence primarily cysteine 
is mutated to serine for protein folding for experimental determination.   
 
 In 2012, the same group published the 3D structure of the N-terminal domain of protein 
HPV16 E6 (PDB 2LJX)
20








This structure contains 84 amino acid residues and has some overlap with that of the C terminus 







Figure 10: Amino acid sequence of E6 prototype highlighting PDB 2LJX (red). This sequence 
was taken for GenBank (GenBank #AAA46939.1). The yellow represents mutations from the 
original sequence primarily cysteine is mutated to serine for protein folding for experimental 
determination. 
 
This structure was also resolved by NMR. This structure combined with the previous 
structure (2FK4) represents a complete structure for E6. However, we proceeded to 
computationally screen each structure individually due to insufficient information to assemble 
both structural domains together. Putting the full structure together computationally would be 
difficult and time-consuming, and the resulting structure may have lacked accuracy.   
 
21 
Just this year (2013) for the first time the full structure of HPV16 E6 was published in 
Science by the same group once again (PDB 4GIZ)
21
 (Figure 11).  
 




This structure was experimentally determined using X-ray crystallography
21
. This structure was 
solved with bound peptides (LXXLL) isolated for Paxcillin and E6AP
21
. This structure contains 





Figure 12: Amino acid sequence of E6 prototype highlighting PDB 4GIZ (red). This sequence 
was taken for GenBank (GenBank #AAA46939.1). The yellow represents mutations from the 
original sequence primarily cysteine is mutated to serine for protein folding for experimental 
determination. 
 
A hydrophobic pocket is formed in the structure between the two zinc domains that are 
connected by a linker helix
21





. This was a big step forward in understanding E6 structurally and its 
interactions with other proteins.  
2.8.STATEMENT OF SIGNIFICANCE 
 Finding a molecular probe of HPV16 E6 that can be used for either diagnostic imaging or 
in a biochemical assay will be very useful in the quest for a further understanding its role in HPV 
infection and HPV-related cancers. An E6-specific molecular probe suitable for medical imaging 
may also lay the foundation for new preventive screening and diagnostic tools, which could one 
day save the lives of many and potentially alleviate some of the burden on our health care 
system.  
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Chapter 3.Methodology and Rational 
3.1.COMPUTATIONAL APPROACHES 
3.1.1.Molecular Docking 
 Molecular docking involves virtually placing a molecule within a protein binding site, 
using computer software
1
. The complexity of the conformational degrees of freedom of both the 
protein and ligand are taken into account
1
. It is critical that these conformations are taken into 
consideration so that the conformation used for scoring is biologically significant
1
. It is important 
that the conformation selected is similar to the conformation in-vivo. The main algorithms 
available for molecular docking can be classified into three approaches: systematic, stochastic, 
and simulation-based methods
2
.   
Systematic approach provides a complete coverage of all reasonable conformations
2
. 
Such an approach is suitable for molecular fragments. Even small molecules have too high a 
number of conformation making this method impractical
2
.  
Stochastic approach is subdivided into two techniques Monte Carlo and Genetic Search 
algorithms. Monte Carlo will generate a random conformation, which is scored, then a series of 
additional random conformations are generated and scored
2
. These conformations are compared 
to the original conformation. Genetic Search algorithms attempt to simulate the random events 
that take place during gene replication in order to generate various conformations
2
.       
Simulation-based methods are molecular dynamics simulations in which a molecular 
system is observed while its energy varies over time in order to observe all theoretical 
conformational states
2
. Such methods can take a long time in order to produce a good sampling 






3.1.2.Virtual Ligand Screening (VLS) 
Virtual ligand screening consists of screening large libraries of chemical compounds 
using computational methods in order to identify candidates with probable biological activity or 
desired properties. Two major subtypes of VLS include descriptor based methods and structure 
based methods. In descriptor based methods the screening of compounds isbased on structural 





, and 3D shape matching
5
. Structural 
based methods are those that use a known 3D structure of the target protein, and the affinity of a 
ligand for its target is evaluated based on how well the ligand is bound to the binding site of the 
protein target
6
. Our particular area of interest is in structural based methods as E6 has no known 
ligands at this point and attempts using pharmacophore modeling or descriptor based approaches 
have been unsuccessful and have demonstrated a need for a known ligand database for E6
7
.  
3.1.3.HierVLS and Scoring Functions 
Hierarchical Virtual Ligand Screening (HierVLS) is a method that uses molecular 
docking to screen large libraries of chemical compounds against proteins. HierVLS will dock a 
large number of conformations of a ligand to a protein which is kept at a fixed conformation 
until the last step in procedure, when the protein is allowed to relax to accommodate the bound 
ligand
8
. This method saves the most expensive computational procedures for the most promising 
conformations
8
. The docked ligands are scored using force fields
8
. Force field based scoring 
functions are commonly used for the estimation of potential energy of protein-ligand 
interactions
9
. These functions are based on principles of classical mechanics, and provide 
accurate potential energy estimates
10
. Force fields describe intramolecular and intermolecular 
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forces as a summation of bonded atoms and non-bonded atoms (Epotential=EBonded+ENon-Bonded)
10
. 
Drieding is the force field used in HierVLS
10
.  
3.1.3. a)Steps in HierVLS 
The first level is level 0: Coarse Grain Conformation Search using  Dock 4.0 software 
package
8
. A scoring function alone with Gasteiger charges
11
 is used to obtain a predefined 
number of protein-bound conformations per ligand in a ligand library
8
. In this level multiple 
conformations of the ligand are docked to the protein in different orientations
8
. To move to level 
1, a docked conformation must pass a user-defined buried surface cut off. This buried surface 
filter is used to eliminate those conformers that do not have the minimum specified amount of 
surface buried
8
. In order to pass through this filter the ligand must be buried at least 70% in the 
field of the protein or otherwise specified. Conformers that meet this requirement will be carried 





. Out of all the conformations energy-minimized in level 1, the top 3 
conformations with the lowest energy will be selected to move to Level 2, which is an all-atoms 
energy minimization
8
. The best (lowest) docked conformer by energy for each ligand is selected 
and used for ligand ranking
8
. The binding energies used for ligand ranking take into account the 
solvation energies associated to the free protein, free ligand, and bound complex. Solvation 
energies are calculated using an implicit solvation model, which allows us to account for solvent 
effects without the explicit inclusion of water molecules
8
. The implicit solvation model used in 
this step is Analytical Volume Generalized Borne (AVGB)
8
. The binding energies are calculated 
as:  
BindE = E (solvated complex)- E (solvated free protein) – E (solvated free ligand)
8
.   
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Through taking the differences, as shown in the equation above, binding energy (BindE) 
between ligand and protein is estimated
8
 (Figure 13). VLS is an effective tool and useful for the 
discovery of a molecular probe, as it is both fast and cost effective.  Computational screening is 
expected to provide a ranked list of potential molecular probes for prototype E6. The HierVLS 













Figure 13: Steps of HierVLS. The best bound conformations are submitted to increasingly 





Experimental ligand binding assays were selected carefully in order to properly 
characterize binding affinity of a molecule keeping in mind the hope of using the molecule as 
either a diagnostic imaging agent or tool for biochemical assays. Experimental approaches have 
been selected in order to not only demonstrate binding but also show that the binding is specific 
as opposed to non-specific. This was be done by demonstrating dose-dependence. Binding assay 
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will either use the protein (tryptophan fluorescence) or the ligand (fluorescence polarization) as 
source of signal. 
3.2.2.Tryptophan Fluorescence 
Since molecules do not have to be fluorescent to be tested in tryptophan fluorescence, 
this method allows us to test affinity without conjugating the molecules to a fluorescent tag, 
which can negatively impact binding affinity. Tryptophan fluorescence is a biochemical assay 
that takes advantage of the indolechromophore naturally present in tryptophan
13
. Tryptophan has 
an observable intrinsic fluorescence that is sensitive to changes in its environment caused by 
conformational changes that occur upon ligand binding
13
. This intrinsic fluorescence is generally 
observed at an excitation wavelength of 288nm and an emission wavelength of 350nm
13
. 
Tryptophan is a rare amino acid in proteins, and is generally only seen once in every polypeptide 
chain
13
. Due to the rareness of tryptophan and its sensitivity to environment, Trp fluorescence is 
an ideal model for tracking conformational change. Changes shown in fluorescence can indicate 
a change in environment of the tryptophan due to ligand binding
13
. This method has been shown 
useful in showing affinity of potential drugs
14
. E6 only contains one tryptophan making this 
method adequate for probing ligand binding (Figure 6). 
This assay will be used to calculate the change in intrinsic tryptophan fluorescence of top 
hit compounds obtained through HierVLS. In all experiments the E6 protein concentration will 
be held constant. Wells and controls are made to represent each ligand on its own at each 
concentration used. This is done in order to make sure that the fluorescence from the background 
is omitted when calculating the percentage change. Solvent controls were also present in later 
experiments, as different solvents will impact the environment of tryptophan differently. Curves 
were taken using and excitation wavelength of 288nm and an emission wavelength of 350nm. 
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Fluorescence intensity values were then manipulated to determine percentage change. A change 
in intrinsic tryptophan fluorescence that is greater than 30% is indicative of a binding event. This 
binding event will be further tested using fluorescence polarization.  
3.2.3.Fluorescence Polarization 
In fluorescence polarization, the fluorescent ligand is excited with polarized light
15
. An 
emission filter is then used to measure the fluorescence intensity emitted by the ligand in both 
the parallel and perpendicular directions
15
. When the ligand is stationary, it is not able to rotate 
or tumble, and the fluorescence emitted is polarized. Thus, the parallel intensity will be greater 
than the perpendicular which results in a higher polarization value
15
. That is the case when the 
ligand is bound to the protein target. When the fluorescent molecule is unbound, the fluorescence 
emitted is depolarized because the ligand is free to rotate. In this case, the parallel and 
perpendicular intensities should be close to equal, resulting in a low polarization value
15
. Thus 
the value of polarization of a system is proportional to the number of occupied binding sites.  
Fluorescence polarization is generally used as a ligand binding assay
16
. This is because of 
the positive correlation between it and the number of occupied binding sites
15
. Therefore a higher 
polarization values means more ligand is bound. This method has a few strong advantages, 
which include high sensitivity, highly reproducible, and its simple mix and read format
15
. Due to 
the dose relationship of fluorescence polarization and these advantages, this method is an ideal 
choice for obtaining a dose-response curve with a fluorescence-tagged lead or an intrinsically 
fluorescent compound. From this method we hope to obtain an accurate EC50 that is in the mid 
or lower micro-molar range to show necessary affinity for probe development. This was shown 
in the recent study where paclitaxel was identified as an inhibitor of botulism neurotoxin A, 





3.2.4.Dose-Response Curves and Curve Fitting 
 A dose response curve is used to track the response proportional to the concentration of a 
stressor
17
. In the case of probe/ drug development this stressor is a molecule binding to its target 
usually a protein. These curves are used for the visualization and calculation of binding constants 
such as EC50
18
. When building such a curve proper fitting methods need to be employed in order 
to accurately determine these constants.  
When fitting a dose-response curve it is important that the properties of the hill slope are 
properly evaluated. The hill equation is traditionally a three parameter equation that shows a 
non-linear relationship between x (independent) and y (dependent) variables
19
. However, an 
additional parameter has been added that accounts for the baseline response giving the equation 
four parameters
19
. The hill equation is used for the fit of experimental data from physiochemical 
reactions
19




The hill equation contains a coefficient known as the hill coefficient. The hill coefficient 
represents cooperative binding
20
. Cooperative binding means that the binding affinity to the 
protein by the ligand is increased upon ligand binding
20
. This binding could even take place at 
other binding sites. This is represented by a hill slope or hill coefficient greater than 1. A hill 
slope that is less than one indicates negative cooperative binding, meaning once the ligand is 
bound its affinity to the protein is decreased
20
. If it is equal to one then the binding is completely 
independent of other binding events
20
.  
 Prism Graphpad (http://www.graphpad.com/scientific-software/prism/) is a program that 
has several curve fitting functions, being widely used in dose-response curve fitting
21
. This 
program contains specific functions used for fitting a dose-response curve. Since we do not want 
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to assume that binding is not co-operative, the four parameter equation was used: Y=Bottom + 
(Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)) was used
21
. In this fitting, the hill slope is not 
assumed to be one. Since the binding of E6 is not understood at an experimental level, 
independent binding was not assumed.  
3.3.CELL BASED METHODS 
      Cell permeability and viability was tested tested for promising compounds from ligand 
binding experiments. The main purpose of these assays is to demonstrate cell permeability and 
specificity within the cell environment. This was conducted using one of two methods. The first 
choice method is to use a microscope capable of inducing and detecting fluorescence. This will 
provide visualization of a binding event using photographs. This method and the other method 
will require the molecule to be labeled with a dye or be intrinsically fluorescent, however 
databases will be created that contain molecules that are suitable for fluorophore attachment. 
Prior to using the microscope cells, were incubated with a predefined concentration of compound 
for a fixed amount of time. These time points vary from one hour of incubation to 24 hours in 
order to get an idea of ligand uptake over time. After the various time points are complete, cells 
were placed under a microscope that induces fluorescence of the molecule and detect it. If the 
molecule has made it successfully through the cell membrane then it should be seen 
accumulating within the cell. Each well containing the drug has a corresponding control well 
containing all ingredients, except the compound, for proper comparison. If proper fluorescence 
filters are not available that match the excitation and emission wavelengths of the promising 
compounds, then an alternative method can be employed.  
The second method uses fluorescence reads from the compound being tested using a 
microplate reader. Wells that contain potential probe were compared to control wells that contain 
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no potential probe. This was carried out by incubating cells with the compound being tested at 
two concentrations for various time lengths, after which cells will by lysed. The lysate was then 
filtered and fluorescence measurements was then taken from each sample and compared to a 
control that contains no compound.  
In order to evaluate whether the compound targets E6 specifically, obtain proper cell 
lines need to be selected. CaSki, SiHa, and C33A cells were used in order to test cell viability, 
permeability and E6 dependency of promising compounds. CaSki contains 200-300 copies of the 
gene coding for E6
22
, whereas SiHa only contains 1-2 copies
23
. C33A cells are cervical cancer 
cells, however they contains zero copies of E6, making them an ideal negative control
24
. Due to 
the varying number of copies of E6 gene in each cell type, if binding is specific we expect higher 
accumulation of the compound being tested in CaSki cells then in the other cell lines, as more E6 
is present. Either method will be sufficient to indicate cell permeability and will give insights on 
specificity. 
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Chapter 4.Materials and Procedures 
4.1.MATERIALS 
O-succinyl –homoserine (MFCD00055782) was ordered from Sigma Aldrich Co in a 
25mg quantity at 98% purity, determined by Sigma Aldrich using TLC.125mg of 3-amino-5-
fluorobenzo [e] [1,2,4] triazine 1, 4 dioxide (AFTD) was ordered from Sunbiochem Inc 
(MFCD14636665) at 98% purity, determined by Sunbiochem Inc using TLC. Paclitaxel was 
ordered from Sigma Aldrich Co (T7402) with a purity of 95% as confirmed by High 
Performance Liquid Chromatography (HPLC). Aminopterin (ALX-440-041-M010) was obtained 
from Enzo Life Sciences Inc, through Cedar Lane Inc, with a purity of 98%. These compounds 
were order and properly stored until usage in ligand binding experiments. Protein E6 was 
ordered from GenScript Inc in both unlabelled and biotinylated form. GenScript Inc determined 
the purity of E6 through the use of Coomassie blue-stained SDS-PAGE gel. Protein was stored in 
a buffer solution to keep the pH at 8.0 (50nM Tris-HCl, 10% Glycerol, pH 8.0). This protein was 
stored at -80C until used in ligand binding assays. CaSki, SiHa, and C33A cell lines were 
obtained through American Type Culture Collection Inc (ATCC).  6F4 E6 monoclonal antibody 
was a gift from the Arbour Vita Co. Dulbecco’s Modification of Eagles Medium (DMEM) 
supplemented with 10% fetal bovine serum and anti/anti was obtained through Fisher Co.  
4.2.COMPUTATIONAL SCREENING 
 Prior to conducting molecular docking, databases of drug like compounds needed to be 
created. The compounds in these databases all shared common drug like properties and had 
characteristics that were suitable for a potential molecular imaging probe for HPV16 E6. Three 
databases were created and screened.   
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4.2.1. a)Primary Amine Database  
 Compounds of this database were downloaded from PubChem
1
. Lipinski’s rule of 5 was 
used as part of the search criteria
2
. A basic primary amine was drawn so that structural similarity 
was searched as well. 2,000 compounds were downloaded. Editing was then conducted to 
eliminate those molecules that contained counter ions and atoms that our docking software 
(Cassandra) cannot process, such as Boron. After editing, 1,153 molecules were left in the 
database. Gasteiger method
3
 was used to calculate partial charges and energy minimization was 
conducted using MMFF94x force field
4
. The database was then saved as a mol2 file in Molecular 
Operating Environment MOE 2010.10 (CC group) 
5
and converted to BGF file format using 
Babel
6
. The BGF file was then cleaned up using an already prepared script (clean_BGF.pl). BGF 
files were then converted into a BGF400FSM files using an additional in house script 
(BGF2BGF4fsm). 
4.2.1. b)Imaging Compound Database   
 Imaging compound database was created using Discovery Gate software
7
.  Lipinski’s rule 
of 5 was used as part of the search criteria
2
. In addition, the "known imaging agents compounds" 
tab was clicked for search criteria. Compounds were then downloaded from Discovery Gate in 
sdf format. Some compounds were edited to eliminate counter ions and atoms that Cassandra 
cannot process. A total of 4,965 were prepared for this database. These compounds were 
imported into MOE 2010.10 (CC group) 
4
, compiled as a database, saved as a mol2 file and 




 was used for calculating partial charges and 
energy minimization was conducted using MMFF94x force field 
2
. The BGF file was then 
cleaned up using an already prepared script (clean_BGF.pl). BGF files were then converted into 
a BGF400FSM files using an additional in house script (BGF2BGF4fsm).  
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4.2.1. c)Fluorine-Containing ligand Database  





 in sdf format. The major search criteria used was Lipinski’s rule of 5
5
. In addition we 
searched for molecules that contained fluorine atoms. This generated a library of 4,146 
compounds, which was used for molecular docking. These compounds were imported into MOE 





was used for calculating partial charges and energy minimization was conducted using 
MMFF94x force field
2
. Mol2 file was converted to BGF using Babel
6
. A BGF file was then 
cleaned up using an already prepared script (clean_BGF.pl). BGF files were then converted into 
a BGF400FSM files using an additional in house script (BGF2BGF4fsm).   
4.2.1. d)Shelf Compounds Database   
 A series of compounds that were readily available within the laboratory were also 





 was used for partial charges were calculated and energy 
minimization was conducted using MMFF94x force field
2
. Mol2 file was converted using Babel
6
 
to a BGF file. A BGF file was then cleaned up using an already prepared script (clean_BGF.pl). 
BGF files were then converted into a BGF400FSM files using an additional in house script 
(BGF2BGF4fsm).  
4.2.2.N-Terminal (PDB 2LJX) Docking 
4.2.2. a)Editing Protein Structure. 
 The structure for the N-terminal domain of HPV16 E6 was downloaded from PDB.org 
(PDB 2LJX). This particular structure contained multiple conformations of HPV16 E6. To 





. The conformations and their binding energies were ranked according to 
total potential energy (Table 3). The best (lowest energy) conformer, conformation 18 with a 
potential energy of -1609.1491kcal/mol, was selected for further analysis.  
Table 3: All conformation in the PDBfile (2LJX). Confirmation 18 was selected for screening. 























Several file types needed to be created for the protein structure (2LJX) (mol2, PDB, BGF, and 
BGF 400 fsm). The structure of the protein is generally saved in MOE 2010.10 (CC group)
5
 as a 
mol2 and PDB files, then scripts were utilized to make the remaining files. Using the program 
Yassara
9
 we were able to save the PDB file with no hydrogen’s. The scripts used included: 
BGF2BGF4fsm and PrepareBGF. 
4.2.2. b)Submitting HierVLS jobs to SHARCNET  
 With the structure files created for the protein and the databases of ligands, jobs could be 
submitted to Shared Hierarchical Research Computing Network (SHARCNET)
10
, using the 
Cassandra interface
11
 to the HierVLS method
12
. SHARCNET is a high performance computer 
cluster, which allows thousands of jobs to run simultaneously. Default parameters (see appendix 
B) were used when submitting all databases except for shelf compounds database, where the 
buried surface area was lowered to 30% because of the large size of some of the molecule. 
4.2.2. c)Analysis of HierVLS Results   
  When each molecule is docked, a series of files are made for each ligand. Files of 
particular interest to our analysis include a BindE table, which contains the raw (force field) 
binding energy score. A BGF file is also present, which contains the ligand bound to the protein 
structure. PDB files are made for the protein that contains the computationally determined 
binding sites as determined by PASS
13
. The N-terminal domain contained two binding sites, R1 
and R2. HierVLS generated 2,911 entries for the N-terminal domain R1, and 6,009 for R2. Force 
field based binding energies for each ligand was taken from the results folders and compiled into 
an excel spreadsheet. This was done by going into each results folder and concatenating the 
BindE energy tables. Each of N-terminus domain two binding sites were individually analyzed. 
Once compiled the mean and standard deviation of the force field scores for all ligands surviving 
 
42 
the HierVLS process were calculated in Excel for each binding region. The binding threshold 
was determined by calculating two standard deviations below the mean for each site. These 
results were imported into Prism 6 (Graph Pad, inc)
14
, where graphs were made to depict these 
results. It was shown that 10 compounds passed the binding/nonbinding threshold for R2 and 
only 3 passed for R1. The 10 molecules that passed the threshold for R2 were examined, as well 
as the three molecules that passed the threshold for R1. Even though all three databases were 
docked, the advantageous properties of the primary amine database and the fluorine containing 
database made these databases first priority. Those compounds from the fluorine containing 
database and primary amine database were further examined to determine commercial 
availability and ligand interaction diagrams were also generated using MOE 2010.10 (CC group) 
5
.  
4.2.3.C-terminus Screening (2FK4) 
4.2.3. a)Obtaining and editing protein structure    
  We obtained our structure for the C-terminal domain of HPV 16 E6 protein using the 
PDB search engine (PDB code 2FK4). Once the structure was downloaded, energy minimization 
was performed MMFF94x force field
4
. The quality of this structure was checked using Procheck 
software
15
. For molecular docking, a few different file types of the protein are required (mol2, 
PDB, BGF, and BGF 400 fsm). The structure of the protein is generally saved in MOE 2010.10 
(CC group)
5
 as mol2 and PDB file formats, then scripts are utilized to make the remaining files. 
Using the program Yassara
9
 we were able to save the PDB file with no hydrogen’s. The scripts 
used included: BGF2BGF4fsm, and PrepareBGF. 
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4.2.3. b)Submitting jobs to SHARCNET HierVLS 
 With the structure files created for the protein and the databases of ligands, jobs could be 
submitted to Shared Hierarchical Research Computing Network (SHARCNET)
10
 using the 
Cassandra
11
 interface to the HierVLS method
12
. SHARCNET is a high performance computer 
cluster, which allows thousands of jobs to run simultaneously. Default parameters (see appendix 
B) were used when submitting all databases except for shelf compounds database, where the 
buried surface area was lowered to 30% because of the size of the molecule. 
4.2.3. c)Analysis of Results  
A script was used to sort through the HierVLS output files and identify molecules in the 
database that were missed in the initial screening (checkruns). The script created a mol2 file, 
which was then turned into BGF and BGF4fsm files using the same methods as described above. 
This was done until all our molecules had been docked, from each database.  When each 
molecule is docked a series of files are made for each ligand. Files of particular interest to our 
analysis include a BindE table, which contains the raw binding energy score. A BGF file is also 
present, which contains the ligand found to the protein structure. In PDB files are made for the 
protein that contains the computationally determined binding sites from PASS
5
.  For case of the 
C-terminal domain 3,339 entries acquired. All force field based binding energy tables were 
concatenated together and transferred into the Excel (Microsoft)
16
 where the binding threshold 
was calculated by as two standard deviations below the mean binding energy of the entire set. 
This was done as we are assuming normal distribution due to the large sample size. Two 
standard deviations will thus give us 95% confidence. Confidence intervals are commonly used 
in statistics to test the validity of an estimate. In our case, it was used to ensure that we select 
those ligands with the highest probability of binding, which are the 5% with the best scores.   
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This binding threshold was used as an ideal screening tool in order to eliminate those 
ligands that have little chance of binding. Using this threshold we went through the fluorine 
containing molecule database as well as the primary amine database to make a selection based a 
selection rational: Observe ligand interaction diagrams to make sure binding is specific, Check 
for commercial availability, obtain toxicology information (Figure 14).  
 
 
Figure 14: Step by step process used for the selection of ligands for C-terminus domain. 
Molecules will selected for experimental ligand binding assays based on these steps  
      
     Five molecules were examined from the fluorine containing database and 3 molecules 
were examined for the primary amine database. Ideally we wanted to select one molecule from 
each database. In order to do so ligand interaction diagrams were created using MOE 2010.10 
(CC group) 
5
. This was easily done as each output file for each ligand contains a BGF file that 
contains the protein structure with the ligand bound. However, to further eliminate compounds 
commercial availability was looked at. Although all molecules were available some were more 
than others (AFTD). In addition some molecules had properties that made them a lot less toxic 
(O-succinyl-L-homoserine). The imaging agents database results can be further examined if 















4.3.TRYPTOPHAN FLUORESCENSE EXPERIMENT 
    3-Amino-5-Fluorobenzo [E] [1,2,4] Triazine-1,4 Dioxide (AFTD) (300M,100M, 
25M,10M,3M,1µM,0.1µM,0.01µM), O-succinyl-L-homoserine (300M,100M, 
25M,10M,3M,1µM,0.1µM,0.01µM,) and Paclitaxel (15M,10M,1M)  were tested in an 
intrinsic tryptophan fluorescence assay at several concentrations with a fixed concentration of 
protein E6 (0.03mg/ml). AFTD and O-succinyl-L-homoserine concentrations were accurately 
measured using a 1mM stock solution dissolved in deionized water, with dilutions prepared 
(100µM, 10µM, 1µM) in order to reach lower concentrations. E6 protein was accurately 
measured from the stock concentration (0.201mg/ml). The assay was buffered to a pH of 7.5 
using 20mM HEPES, 0.01% tween (v/v) and incubated to a temperature of 37C. Control wells 
were included for the protein alone, AFTD, O-succinyl-L-homoserine, and paclitaxel (at each 
concentration tested). Samples were plated as triplicate wells, and duplicate wells for all controls, 
in a 96-well black bottom microplate (Nunclon®).The experiment was run using a Synergy 4 
Microplate Reader (Biotek). The monochromator was used to collect emission spectrums for 
each well from 310nm-700nm at an excitation of 288nm. Fluorescence intensity was read using a 
probe height of 4mm, a 150 sec delay between wells, and 20 reads per well. Data was collected 
every 30 minutes for 60 minutes using a sensitivity value of 100 with Gen5 software (Biotek)
17
. 
The read settings and filter/mirror combination were optimized during preliminary experiments. 
Changes in intrinsic tryptophan fluorescence were calculated using Prism 6 (Graph Pad, Inc)
4
 
baseline reduction functions.   
Water, buffer, and required solvent were added first to all the wells in the microplate. 
Once water buffer and solvent were added the ligands and antibody were measured out 
accurately using the stock solutions made at the desired concentrations. The reaction was 
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initiated with the addition of E6 protein (0.03mg/ml) after which the plate was incubated in the 
plate reader under the conditions specified above.   
4.3.1. a)Data Analysis   
 Fluorescence intensity readings were imported into Excel 2010 (Microsoft, Inc)
2
 then 
directly imputed into Prism 6 (Graph Pad, Inc)
14
. Means and standard errors were calculated 
using Prism 6 (Graph Pad, Inc)
14
for all duplicate and triplicate wells using column statistic 
function. For each sample containing protein plus ligand, the background for each corresponding 
ligand at the appropriate concentration was deducted using baseline column math 
(Difference=Value-Baseline)
14
. Each individual ligand concentration on its own was assigned as 
the baseline for the corresponding sample, in order to deduct the background from the ligand. 
Baseline column math, was once again performed or each ligand and concentration, this time 
assigning the protein with  corresponding solvent, as the baseline value to generate the percent 
change values for each wavelength (%difference:= 100*(value-baseline)/baseline))
14
. The 
baseline was assigned as the proper protein control depending on sample and concentration. The 
350nm  percent change values were then plotted in a bar graph with error bars representing the 
standard error that was propagated by Prism 6 (Graph Pad, Inc)
14
. In addition fluorescence 
intensity curves for each ligand concentration were also made from the background reduced 
values.   
4.4.CHARACTERIZATION OF AFTD 
4.4.1.Spectroscopy Characterization of AFTD 
      Characterization was conducted for 3-Amino-5-Fluorobenzo [E] [1,2,4] Triazine-1,4 
Dioxide (AFTD) using a 50M concentration. Experiment was run using a BioTek Synergy 4 
Microplate reader. Using a microplate (Costar) 96 well black bottom for emission spectrum and 
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a clear microplate (Falcon) 96 well plate was used for absorbance and excitation spectrums. 
Sample was buffered to a pH of 7.5 (20mM 7.3 HEPES, 0.01% tween (v/v)) and ran at 37C. A 
blank well that contained buffer (20mM 7.5 HEPES) and water was also used. All wells were 
topped up with distilled water to a final volume of 100 L. Initially an absorbance spectrum was 
run by collecting values every 5nm. This indicated a maximum absorbance at 270nm. This value 
was used as excitation wavelength for the emission spectrum, which was run from 300-700nm at 
a sensitivity of 100. Emission spectrum indicated a maximum emission at 535nm. This value was 
then used to run an excitation spectrum in the Falcon clear plate from 250-700nm. This indicated 
that the maximum excitation was at 260nm with a secondary peak at 435nm. In addition, the 
secondary peak max was found at 435nm. Emission spectrum was re-run using 260nm instead of 
270nm from 300-700nm using a sensitivity of 100. Once again the maximum emission was 
shown to be 535nm. From these results, a suitable excitation filter (460/40nm), emission filter 
(528/20nm) and dichromatic mirror (510nm) were identified for use in the binding assays.     
4.4.2.Standard Curve and AFTD Equilibrium 
       A standard curve for AFTD was made by testing 6 concentrations (300M, 100M, 
50M, 25M, 10M, 1M). This was done using a sensitivity of 80 in a microplate (Nunclon®) 
at a pH of 7.5 (20mM HEPES, 0.01% tween (v/v)) at an incubation temperature of 37ºC. 
Fluorescence intensity values were taken using a filter set combination (Ex 460/40nm, Em 
528/20nm, and dichromatic mirror 510nm). The 25µM AFTD was also included in well with a 
set amount of E6 protein (0.04mg/ml) as a single point. Reads were taken every 15minutes under 
the same conditions described for the standard curve except fluorescence intensity values were 
taken in both the perpendicular and parallel directions to calculate polarization. This was done in 
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order to determine the time point our system reaches equilibrium.  Data analysis was conducted 
as described in section 4.5.1.  
4.5.FLUORESCENCE POLARIZATION CONCENTRATION CURVE TO 
DETERMINE EC50 
AFTD was tested in a fluorescence polarization assay at seven concentrations 
(300M,100M,50M,25M,15M,10M,1M) with a fixed concentration of protein E6 
(0.04mg/ml). AFTD concentrations were accurately measured using 1mM and 100µM stock 
solutions dissolved in half water/half ethanol. E6 protein was accurately measured from the stock 
concentration (0.201mg/ml). The assay was buffered to a pH of 7.5 using 20mM HEPES, 0.01% 
tween (v/v) and incubated to a temperature of 37C. Control wells were included for the protein 
alone, and AFTD without protein at each concentration tested. Samples were plated as duplicate 
wells in a 96-well black bottom microplate (Nunclon®).The experiment was run using a Synergy 
4 Microplate Reader (Biotek). An excitation filter (460nm/40) and emission filter (528nm/20) 
were used with a dichromatic mirror (510nm). Fluorescence polarization was read using a probe 
height of 4mm, a 350 sec delay between wells, and 40 reads per well. Data was collected every 
15 minutes for 75 minutes using a sensitivity value of 80 with Gen5 software (Biotek). The read 
settings and filter/mirror combination were optimized during preliminary experiments. 
Fluorescence polarization values were calculated with blank values discounted.   
          The reaction was initiated by first adding water, solvent, and buffer. Once these amounts 
were measured into the reaction wells AFTD was then accurately added from the 1mM or the 
100µM stock solutions. Once all ingredients were in each well the protein was added to each 
protein-containing well from the stock solution to initiate the binding reaction. After which the 
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plate was incubated in the microplate reader under conditions described above. Readings were 
taken every 15 minutes starting at time zero to 120 minutes using Gen5 software (Biotek)
17
. 
4.5.1. a)Data Analysis   
Data was exported into Excel 2010 (Microsoft, Inc)
16
 from Gen5 (Biotek), where values 
for parallel and perpendicular intensities were manipulated for each time point. The blank was 
discounted by hand using excel in both perpendicular and parallel directions. The perpendicular 
values were manipulated using an experimentally determined G-Factor (0.96) (G-Factor=Parallel 
intensity*(1-0.02)/ Perpendicular intensity (1+0.02))
17
. Calculating the G-factor is required to 
correct for instruments that have a variety of different optical designs. Using these values 
polarization was calculated in Microsoft excel according to equation (Polarization= ((parallel-G-
factor*perpendicular)/ (parallel+ G-Factor* perpendicular))
17
. Values were then imported into 
Prism 6 (Graph Pad, inc)
14
 where graphing and curve fitting took place. The second well value 
for polarization in the 300 µM was dropped from this calculation as it was inconsistent across the 
time points. The error bars represent the standard error of the duplicate polarization values. EC50 
was estimated using Prism’s non-linear dose-response fitting function (four parameters)
14
.  
4.6.CELL BASED ASSAYS 
4.6.1.Cell culturing 
4.6.1. a)Cell lines and Routine Maintenance   
 CaSki, SiHa, and C33A cells were obtained for ATCC. CaSki cells contain 200-300
18
 
copies of E6 protein, whereas SiHa only contain 1-2 copies
19
. C33A cells contain zero copies of 
E6
20
. All cells were cultured in DMEM complete medium (10% fetal bovine serum and 1X 
anti/anti) obtained through Fisher Co. Cells were held in an incubator at constant conditions 
(37C, 5% C02). These cells were feed every 2-3 days and split when they reached 60-80% 
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confluent.  All cells were routinely screened for Mycoplasma contamination, which is a common 
contaminant in cell cultures and none was found.  
4.6.1. b)Freezing and Storage   
Freezebacks were made by adding 10% DMSO to complete DMEM medium. Cells were 
then frozen at -80C then moved into liquid nitrogen.        
4.6.1. c)Thawing Cells  
Cells were taken out of liquid nitrogen then added to 10ml of complete medium (DMEM) 
and centrifuged for 5 min at 750rpm. Centrifugation is used in order to make sure that all DMSO 
is removed from the cells as this can be cytotoxic. Cells are then, re-suspend in clean complete 
medium in a T75 flask (Fisher, Inc).  
4.6.2.Cell Viability 
 Cells were prepared as described in routine maintenance. Cells were then removed from 
flasks and seeded into 24 well plates (flat bottom, Fisher). Approximately 25,000 cells were in 
each well prior to application of AFTD. AFTD was added to the cells (CaSki, SiHa, and C33A) 
24 hours after seeding. This was done by adding a calculated amount of AFTD stock (2mM) in 
complete medium (DMEM) accurately for each concentration (25µM and 10µM) used to make 
up treated medium which was added directly to each well (500µL). The effect of ethanol, used as 
solvent for AFTD, was controlled by adding the same volumes respectively for each 
concentration (25µM and 50µM) of a solution that contained half ethanol and half de-ionized 
water. The original medium (500µL) in each well was removed and the treated medium 
containing AFTD and control medium, which contained ethanol was then added (500µL). For 
each time point, there were three treated wells with AFTD at each concentration tested and 3 
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controls, which were treated with ethanol at the same percentage by volume as the corresponding 
concentration. Enough medium was made for all the plates created to serve each time point (3, 6, 
12, and 24). Since no change was observed using a light microscope after 3 and 6 hours, the next 
time point observed was at 24 hours.    
4.6.3.AFTD Cell Permeability 
 AFTD was added to each plate as described in (Section 4.5.2). However, the final 
concentrations in medium were 25µM and 50µM. Different time points were also used (1hour, 
2hours, and 3hours). Plates were removed from the incubator at corresponding time points. Cells 
were then rinsed in 1X Phosphate Saline Buffer (500µL) of and then lysed for 1hour in lysing 
buffer (55% water, 32%DMSO, and 13% triton). The lysate was taken and transferred to 2ml 
centrifuge tubes and centrifuged at 750rpm for 5 minutes. The supernatant was added to a 
Nunclon® 96 well microplate at a volume of 100µL per well. Fluorescence was read using a 
Biotek Synergy 4 Microplate reader using an optical system that consisted of an excitation filter 
(460/40nm), emission filter (528/20nm), and mirror 510nm. 350µs delay was used with a 4mm 
probe height, 40 reads per well, and a sensitivity of 100. In addition, absorbance was also taken 
at 260nm, 280nm, and 535nm to control for cell density.    
4.6.3. a)Data Analysis      
 Absorbance and fluorescence intensity for each time point was collected using Gen5 
(Biotek) software. These values were then imported into Excel 2010 (Microsoft, Inc)
16
. Due to a 
large amount of bubbles in the microplate, the 1hour time point was omitted from analysis. The 2 
hour and 3 hour time points were analyzed by importing values into Prism 6 (Graph Pad, Inc)
14
, 
where means and standard deviations were calculated for each of the triplicate samples. The 
means and standard deviations were calculated using Prism 6 (Graph Pad, Inc) column statistics 
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analysis. These values were then graphed as bar graphs. Sidak’s multiple comparisons ANOVA 
was conducted using Prism 6 (Graph Pad, Inc) software
14
. This will calculate if any difference 
between the sample and its corresponding control is significant within a 95% confidence interval.  
Turbidity (optical density) at 535nm was used to verify that the density of cells in each sample 
and control wells were comparable. If there were discrepancies, then the measured fluorescence 
values would have to be corrected for the difference in cell density. Optical density values at 
535nm were about the same for each well and, for this reason, no correction was needed.  The 
ratio of absorbance values at 260nm (nucleic acids) and 280nm (proteins) was used to further 
verify that the cell cultures in each well were consistent. 
4.7.6F4 ANTIBODY COMPETITION EXPERIMENT 
A competition experiment was conducted varying the concentration of antibody 6F4 
against fixed concentrations of AFTD (6M) and E6 (0.04mg/ml).  The concentrations of protein 
and AFTD were chosen based on the EC50 value determination of 6M at a protein 
concentration of 0.04mg/ml (Section 5.4). The experiment was conducted using a 96 well 
Nunclon® black bottom microplate at 37C and buffered to a pH of 7.5 (20mM 7.5 HEPES 
0.01% tween (v/v)) in a Synergy 4 BioTek microplate reader. The AFTD 6M wells were 
measured from a 100M stock solution. The 100µM AFTD stock solution was diluted using de-
ionized water from a 1mM stock solution in 2ml centrifuge tube. The 1mM AFTD stock solution 
was dissolved half ethanol half de-ionized water. All wells containing AFTD were topped up 
with 15µL of ethanol to make sure it did not precipitate out of solution. Antibody 6F4 
concentrations varied from 4ng/ml all the way to 4x10
-6
ng/ml using 10 fold dilutions from a 6F4 
antibody stock solution (2.69mg/ml). A standard antibody control with the antibody on its own in 
buffer solution was present at the highest concentration in a single well. A single protein control 
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well was also present. Controls wells were also present for the antibody at each concentration 
used (4ng/ml-4x10
-6
ng/ml) with AFTD (6M). The ethanol was controlled by making sure each 
well controls and samples contained a consistent amount of ethanol (15µL). All wells were 
topped up to 100µL using deionized water.  Perpendicular and parallel fluorescence intensity 
values were collected every 15 minutes using an optical system that consisted of an excitation 
filter (485/20nm), emission filter (528/20nm), and 510nm dichromatic mirror with a sensitivity 
of 80, a probe height of 4mm and a time delay of 350µsec per well. 
4.7.1. a)Data Analysis     
 Manipulation of data to calculate polarization values were done in the same fashion as 
described in 4.4.1a).One of the 4ng/ml of antibody 6F4 was omitted from the dataset as 
inconsistencies were observed. Polarization was plotted against concentration of antibody in a 
log scale to see if any concentration-dependent behaviour had taken place.    
4.8.O-SUCCINYL-L-HOMOSERINE CONJUGATE 
4.8.1.Synthesis of O-succinyl-L-homoserine-Bodipy 
O-Succinyl-L-homoserine-Bodipy was synthesized using 1:1:1 equivalents of Bodipy-
NHS, O-succinyl-L-homoserine, and triethylamine under argon gas. Reaction was initiated by 
dissolving 5mg of Bodipy in 500µL of dimethylformamide (DMF). The reaction vial was placed, 
with stirring, in a water/ice bath at 0ºC. While in the water/ice bath, one equivalent (2.730mg) of 
O-succinyl-L-homoserine was added and mixed, followed by 1.39µL of triethylamine. The 
remainder of the reaction vial was filled with argon gas. The reaction was left to proceed for 30 
minutes at 0ºC after which the vial was removed from the water/ice bath. Once removed from the 
water/ice bath, the reaction vial was left to stand at room temperature overnight. Separation was 
performed using water and a small amount of ethyl acetate. Our product was found to be in the 
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aqueous phase. This was confirmed using TLC (5:1 dichloromethane:methanol). Purity was also 
verified at 95% using TLC (5:1 dichloromethane:methanol). The sample was then freeze dried, 
and stored at -20°C. 3mg of product was obtained from this reaction. Liquid chromatography 
mass spectrometry (LC-MS) was used to confirm the identity of O-succinyl-L-homoserine-
Bodipy(supplementary  information).   
4.8.2.Spectroscopic Characterization of O-succinyl-L-homoserine-Bodipy 
Characterization of O-succinyl-L-homoserine-Bodipy was conducted using a 50µM 
concentration. This was conducted at 22ºC in a Synergy 4 microplate reader (BioTek) buffered to 
a pH of 7.5 (20mM HEPES, 0.01% tween (v/v)). Absorbance spectrum was conducted using a 
microplate (Falcon) clear 96 well and absorbance spectrum was acquired collecting data every 
5nm. An absorbance spectrum indicated a maximum absorbance at 500nm. This value was used 
as the excitation value to conduct an emission spectrum using a sensitivity of 70 and a probe 
height of 4mm with the same concentration of O-succinyl-L-homoserine-Bodipy (50µM) and 
was conducted in a black bottom microplate (Nunclon®). This demonstrated a maximum 
emission of 510nm. This value was then used as the emission wavelength to conduct an 
excitation spectrum at the same concentration sensitivity and probe height. The maximum 
excitation was confirmed to be 500nm. These values allowed us to determine a proper filter set 
combination to be used in the ligand binding assays, which includes an excitation filter 
(485/20nm) emission filter (528/20nm) and a dichromatic mirror (510nm).  
4.8.3.Fluorescence Polarization Assay 
 O-succinyl-L-homoserine-Bodipy was tested in a fluorescence polarization assay at three 
concentrations (1, 10, and 100M) with a fixed concentration of protein E6 (0.04mg/ml). The 
assay was buffered to a pH of 7.5 using 20mM HEPES, 0.01% tween (v/v) and incubated to a 
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temperature of 37C. Control wells were included for the protein alone, and O-Succinyl-L-
homoserine-Bodipy alone (at each concentration tested). Samples were plated as single wells in a 
96-well black bottom microplate (Nunclon®).The experiment was run using a Synergy 4 
Microplate Reader (Biotek). An excitation filter (485nm/20) and emission filter (528nm/20) were 
used with a dichromatic mirror (510nm). Fluorescence polarization was read using a probe 
height of 4mm, a 350sec delay between wells, and 40 reads per well. Data was collected every 
15 minutes for 75 minutes using a sensitivity value of 65 with Gen5 software (Biotek). The read 
settings and filter/mirror combination were optimized during preliminary experiments. 
Fluorescence polarization values were calculated with blank values discounted.  A standard 
curve was also included for the concentrations tested and included in the characterization of this 
molecule.  
4.8.3. a)Data Analysis    
 Manipulation of data to calculate polarization values was done in the same fashion as 
described in 4.4.1a). The second well value for polarization in the 4ng/ml well was dropped from 
this calculation as it was inconsistent across the time points. Each concentration tested was 
plotted against time. The error bars represent the standard error of the duplicate polarization 
values.   
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Chapter 5.Results and Discussion 
5.1.COMPUTATIONAL SCREENING 
      Computational screening was conducted using two different structures of HPV16 E6, in 
order to make sure both C-terminus and N-terminus domains were analyzed. This will allow us 
to be able to properly evaluate potential lead compounds that can then be used for further 
experimental testing. Note that the C-terminus domain was published first so more extensive 
analysis was conducted and the N-terminus was used in order to make further suggestions on 
potential molecular probes. Three libraries of molecules were downloaded using both PubChem 
and Discovery Gate online services. These libraries comprised a total of 10,264 molecules. One 
library was of known imaging agents; however, due to the lack of availability of these molecules 
and advantageous functional groups of the other databases, these were not fully examined. One 
of the other databases contained molecules with one or more fluorine atoms, which is 
advantageous for Positron Emission Tomography (PET). The third database was composed of 
molecules that contain a primary amine functional group. The primary amine compounds are 
suitable for labelling with amine-reactive fluorescent dyes available commercially. This 
represents a challenge in the identification of hits from this library. Compounds with promising 
binding energies to the target structures (hits) were selected for experimental testing from the 






5.1.1.N-Terminus Computational Screening (2LJX) 
 
Figure 15: Full surface structure of 2LJX N-terminal structure of E6. The red dotes show the two 
binding sites R1 and R2 as determined by PASS
1
.   
 
All three databases were computationally screened against the N-terminal domain of 
HPV16 E6 (2LJX) using Virtual Ligand Screening (VLS). Through examining the potential 
energy of each confirmation, it was concluded that the structure (2LJX) was in good shape for 
molecular docking. Two binding regions (R1 and R2) were identified  within this domain (Figure 
15) using PASS
1
.  Non-binder/binder thresholds were calculated for each region of the structure 
(Table 4).  
Table 4: Summary of HierVLS results for N-terminal domain of HPV16 E6 (2LJX)   











R1 10,264 2,911 -53.12 3 
R2 10,264 6,009 -58.20 10 
 
Non-binder/binder threshold was calculated as the mean of the full data set for each 
binding site plus two standard deviations from the mean. Assuming normal distribution, the 
selected ligands will be at the 95% confidence interval. For R1 this threshold was calculated to 






Figure 16: Scatter plot of results from the computational screening of NT-E6 (PDB code 2LJX) 
for binding region 1 (R1). The solid black line represents the mean score for the entire library 
docked to NT-E6.The dotted lines represent plus or minus two standard deviations from the 
mean, which was used to determine a binding threshold of -58.20kcal/mol. A total of three 
molecules passed the binding/nonbinding threshold. The complete list of hits passing the  




Figure 17: Scatter plot of results from computational screening of 2LJX for R2. The solid black 
line represents the mean and the dotted lines represent plus or minus two standard deviations. 
This was used to determine a binding threshold of -58.20kcal/mol.  A total of 10 molecules based 
the binding/nonbinding threshold. The complete list of hits passing the threshold for R2 is 









Table 5: Compounds that passed the R1 threshold of -53.12kcal/mol. Refer to table A for 
molecular structures 
Rank Identifier Binding Score 
(kcal/mol) 
IUPAC name Smiles 

























































Table 6: Compounds that passed the threshold of -58.20kcal/mol HierVLS targeting regions R2 
in NT-E6. Refer to Table B for molecular structures. 
Rank Identifier  Binding Score 
(kcal/mol) 
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The compounds solanesyl-pyrophosphate, aminopterin, and paclitaxel were already available in 
the lab. However, information regarding vendors for the three other molecules needed to be 
obtained using information stored in the database (Table 7). Based on commercial availability, 
the compounds in Table 7 were recommended for experimental testing.  




























































In addition to commercial availability, these ligands were also found to have specific 
interactions to the protein according to their HierVLS-predicted ligand-protein structures. Ligand 
interaction diagrams were generated using MOE 2010.10 (CC group)
2
 and used to identify 
specific interactions between ligand and protein. The ligand interaction diagram for 3-Chloro-2-
(2-[(3-oxo-2-Benzfuran-1 (3H)-Yliden] methyl) Hydrazino)-5-(Trifluoromethyl) Pyridinum 
Acetate bound to the NT-E6 (2LJX) shows the following non-bonded interactions between the 
ligand and protein E6: Hydrogen bonds Cys51 and Arg10 (Figure 18). 
 
Figure 18: Ligand interaction diagram of 3-Chloro-2-(2-[(3-oxo-2-Benzfuran-1 (3H)-Yliden] 
methyl)Hydrazino)-5-(Trifluoromethyl) Pyridinum Acetate bound to N-terminal E6 (NT-E6).   
 
 The ligand interaction diagram for 3-Chloro-2-(3-[1-(Phenyl sulfonyl)-(H-pyrazol-3-YL] 
Phenoxy)-5-(Trifluoromethyl) Pyridine bound to the NT-E6 (2LJX) shows the following non-
bonded interactions between the ligand and protein E6: Hydrogen bonds Cys51 as well as an 




Figure 19: Ligand interaction diagram of 3-Chloro-2-(3-[1-(Phenyl sulfonyl)-(H-pyrazol-3-YL] 
Phenoxy)-5-(Trifluoromethyl) Pyridine bound to N-terminal E6 (NT-E6).     
 
 The ligand interaction diagram for N-(2,4-dinitrophenyl)-L-arginine ) bound to the NT-
E6 (2LJX) shows the following non-bonded interactions between the ligand and protein E6: 
Hydrogen bonds Cys51 and Arg10 (Figure 20). 
 
Figure 20: Ligand interaction diagram of N-(2,4-dinitrophenyl)-L-arginine to N-terminal E6 





Based on these interactions we can conclude that these molecules interactions are specific to E6, 
making them highly favourable potential candidates for molecular probe development.  
5.1.2.C-Terminus Computational Screening (2FJK) 
 
Figure 21: Surface representation of Protein E6 C-terminal domain (2FK4). The red dot 




All three databases were also docked to the C-terminus HPV16 E6 structure (CT-E6), 
with PDB code 2FK4, which only had one binding region identified by Pass
1
 (Figure 21). Prior 
to docking the protein structure (PDB 2FK4) was checked for quality of dihedral angles using a 
Ramachandran Plot (Figure 22). Most of these angles were found in the allowed region and for 





















Figure 22:  Ramachandran plot of HPV16 E6 C-terminal domain (PDB 2FK4)  The plot was 
generated using MOE 2010.10 and used to check the dihedral angles of the experimentally 
determined structure prior to docking. 
 
The screening of these databases against one binding site of E6 using a high performance 
computer cluster at the Shared Hierarchical Academic Research Computing Network 
(SHARCNET)
3
. A binding/nonbinding threshold (-35.47Kcal/mol) was established as the mean 
binding energy of the entire 3,339 compounds set plus two standard deviations from the mean 
(Figure 23). A summary of this screening is laid out in Table 8.   


















Figure 23: Force field scores for 3,339 compounds docked to CT-E6.  binding/nonbinding 
threshold (-35.47Kcal/mol) was established as the mean binding energy of the entire 3,339 
compounds set plus two standard deviations from the mean 
 
. Establishing a statistical threshold is necessary because there are no available known small-
molecule binders to HPV16 E6 that could be docked to the structure and used as reference. 
Using this non-binder/binder threshold, three compounds from the primary amine database and 
five from the fluorine-containing database were selected for further analysis (Tables 9 and 10, 
respectively). 
Table 9: Top three compounds from the primary amine database in order of rank. All molecules 

































Table 10: Top 5 compounds from the fluorine-containing molecule database in order of rank. All 
these compounds passed the binding/nonbinding threshold of -35.47kcal/mol. Refer to Table E 
for molecular structures  
 
Both, the top three primary amines and top five fluorine-containing compounds, were further 
evaluated for commercial availability and safety, in addition to presence of specific ligand-
protein binding interactions, as determined by ligand interaction diagrams created using MOE 
2010.10 (CC group)
4
. These diagrams allow the visualization of the interactions that the ligand 
has with the residues of the protein. These interactions validate the binding energy score, since 
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favourable binding energies should correspond to specific interactions between ligand and 
protein.  
The ligand interaction diagram for 3-Amino-5-Fluorobenzo [E] [1,2,4] Triazine-1,4 
Dioxide (AFTD) shows hydrogen bonds (HBs) from the ligand to the Lys45, and Arg58 residues 
of the CT-E6 (2FK4) structure (Figure 24). These HBs indicate specific interactions between the 
partners, as opposed to non-specific atomic interactions. The ligand interaction diagram for O-
succinyl-L-homoserine bound to the CT-E6 (2FK4) shows the following non-bonded 
interactions: HBs Arg40, Lys45, and Glu37 as well as a metal/ion contact with Arg40 (Figure 
25). The presence of these non-bonded interactions justify the favourable binding energies 
calculated for this complex and, hence, increases our confidence that binding of this ligand to the 
target protein will be specific. This would be observed experimentally as a ligand concentration-
dependent binding response. 
 
Figure 24: Ligand interaction diagram of 3-Amino-5-fluorobenzo [E] [1,2,4] Triazine 1, 4 





Figure 25: Ligand-protein interactions diagram of O-succinyl-L-homoserine bound to C-terminal 
(CT-E6). 
 
With the objective of performing experimental assays, compounds that were not available 
commercially or were not safe to work with were deemed not useful for our purposes regardless 
of their binding energy score, and were eliminated from our list. Based on our selection criteria, 
O-succinyl-L-homoserine (O-succinyl) and 3-Amino-5-Fluorobenzo [E] [1,2,4] Triazine-1,4 
Dioxide (AFTD) were selected for experimental testing (Table 11).  Additionally, two of the 
shelf compounds, paclitaxel (-70.10 kcal/mol) and aminopterin (-59.61 kcal/mol), were found to 
have sufficiently high binding energy (above the non-binding/binding threshold), to justify 
experimental testing. The ligand interaction diagram for paclitaxel bound to the CT-E6 (2FK4) 
shows the following non-bonded interactions: H-bonds Arg 58, Lys45, and Arg40 (Figure 26). 
The ligand interaction diagram for Aminopterin bound to the CT-E6 (2FK4) shows the following 
non-bonded interactions: H-bonds Try7, Lys45, and Gln46 (Figure 27). Due to these specific 
interactions for both compounds, we expect binding to be specific.  
The binding of all four compounds to the protein was assessed experimentally using 























Table 11: Ligands selected for experimental testing. All four ligands were selected based on 
binding scores, ligand interactions to the protein, and commercial availability. Refer to Table F 




















1,4 Dioxide  
12 -49.53 AFTD Fc1c2[n+]c(n[n+]([O-])c2ccc1)N 
Aminopterin 8 -59.61 Amino O=C(O)C(NC(=O)C1CCC(CC1)N
CC2NC3C(NC2)NC(NC3N)N)CC
C(=O)O 






5.2.INTRINSIC TRYPTOPHAN FLUORESCENCE EXPERIMENT 
Intrinsic tryptophan fluorescence assays were employed in order to test against E6 
ligands from computational screening that are not fluorescent labelled or intrinsically 
fluorescent. In these assays we hope to observe a change in the protein's intrinsic tryptophan 
fluorescence that is greater than 30% in the presence of the ligand. This will indicate a 
significant change to the environment of the tryptophan, suggesting a binding event. Principles 
of tryptophan fluorescence are outlined in the methodology section of this thesis (3.2.2).  
The tryptophan (Trp) fluorescence assay was performed for paclitaxel, O-succinyl-L-
homoserine and AFTD in an attempt to obtain binding constants which would facilitate the 
fluorescence polarization dose-response curve assay. The ligands were tested at 300M, 100M, 
25M, 10M, 1M, 0.1M, and 0.01M. Paclitaxel was tested at 15M, 10M, and 1M in 
order to make sure it did not precipitate out at higher concentrations as it is not soluble unless the 
 
73 
concentration of DMSO is high. We wanted to keep the concentration of DMSO low as it could 
denature E6 protein. Preliminary experiments showed that a protein concentration of 0.02mg/ml 
was sufficient to obtain a good signal (See appendix A). However, to improve signal even 
further, the protein concentration was increased to 0.03mg/ml. Proper solvent controls were 
provided for DMSO, which is used to solvate paclitaxel. Unfortunately, our instrumentation 
setup was not adequate for obtaining emission spectra in the < 340 nm range with excitation at 
288 nm.  This prevented the use of intrinsic Trp fluorescence for determining binding constants. 
We instead used the percent change at 350 nm emission to probe binding. Percent change (% 
change) was considered indicative of binding if > 30%. An E6-specific antibody (6F4) was used 
as positive control and induced a change greater than 30%. The change in intrinsic fluorescence 
induced by   3-Amino-5-Fluorobenzo [E] [1,2,4] Triazine -1, 4 Dioxide (Figure 28) shows 
concentration-dependency, whereas the presence of O-succinyl-L-homoserine induces quenching 
albeit not concentration-dependent (Figure 29). In addition, concentration dependence was 





Figure 28: Change in intrinsic tryptophan fluorescence at 350nm induced by 3-Amino-5-
Fluorobenzo [E] [1,2,4] Triazine-1,4 Dioxide (AFTD) after 30minutes incubation in the presence 
of E6. A) Fluorescence intensity. B) Bar graph %change. C) log scale % change plot. D) AFTD 
300µM (black) and protein alone (red). Reaction was incubated at a temperature of 37C and 
buffered to a pH of 7.3 (20mM HEPES 7.3, 0.01% tween (v/v)). Protein concentration was held 
constant at 0.03mg/ml. 6F4 antibody was used as a positive control at a concentration of 
0.4ng/ml AFTD concentration was varied (300µM-0.01µM). The red line in graph B represents 
the 30% change baseline. Experiment was validated by our positive control, 6F4 antibody, 




Figure 29: Change in intrinsic tryptophan fluorescence at 350nm induced by O-succinyl-L-
homoserine after 30minutes incubation in the presence of E6. A) Fluorescence intensity. B) Bar 
graph %change. C) log scale % change. D) Plot of O-succinyl-L-homoserine 300µM (black) and 
protein alone (red). Reaction was incubated at a temperature of 37C and buffered to a pH of 7.3 
(20mM HEPES 7.3, 0.01% tween (v/v)). Protein concentration was held constant at 0.03mg/ml. 
6F4 antibody was used as a positive control at a concentration of 0.4ng/ml. O-succinyl-L-
homoserine concentration was varied (300µM-0.01µM). The red line in graph B) represents the 
30% change baseline. Experiment was validated by our positive control, 6F4 antibody, 
producing a change above 30%. The effect of O-succinyl-L-homoserine did not follow a 
concentration-dependence, however showed multiple concentrations where quenching above 




Figure 30: Change in intrinsic tryptophan fluorescence at 350nm induced by Paclitaxel after 30 
minutes incubation in the presence of E6. Reaction was incubated at a temperature of 37C and 
buffered to a pH of 7.3 (20mM HEPES 7.3, 0.01% tween (v/v)). A) Bar graph % change. B) 
%change log scale concentration. C) Protein alone 15M control (red) and paclitaxel on its own 
15M (black).  Protein concentration was held constant at 0.03mg/ml. 6F4 antibody was used as 
a positive control at a concentration of 0.4ng/ml. Paclitaxel was tested in three concentrations 
(15µM, 10µM, and 0.01µM). The dotted line in graph A) represents the 30% change baseline. 
Experiment was validated by our positive control, 6F4 antibody, producing a change above 30%. 
The effect of paclitaxel is concentration-dependent. 
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Although O-succinyl-L-homoserine did not show concentration-dependence it still induced a 
change in fluorescence greater than 30% at some concentrations. However, further ligand 
binding assays are needed before we can conclusively say binding has occurred. Paclitaxel will 
also need to be further tested for verification. The antibody used also appears to be giving 
inconsistent results. This is believed to be due to the antibodies sensitivity to the environment 
and the lack of sodium azide in the antibody's buffer. Sodium azide is usually in antibody buffers 
to prevent microbial contamination. Since the antibody had been in and out of the fridge between 
experiments, contamination might have occurred. In addition the antibody may have denatured 
or degraded when exposed to the external environment even for a short period of time.   
5.3.CHARACTERIZTION OF AFTD 
5.3.1.Spectroscopic Characterization of AFTD 
   In order to determine a proper filter set for AFTD, spectroscopy characterization needed to 
be conducted. Through this characterization a maximum excitation at 260nm with a second 
maximum at 435nm, and a maximum emission at 535nm was determined (Figure 31). This 
allows us to decide on a proper filter set suitable for AFTD, which contained an excitation filter 






Figure 31: Excitation/Emission spectrum of 3-Amino-5-Fluorobenzo [E] [1,2,4] Triazine-1,4 
Dioxide (Fluoro). Experiment was run at 37C at a pH of 7.5 (20mM 7.3 HEPES, 0.01% tween 
(v/v)). A maximum excitation was observed at 260nm with a secondary max at 435nm. 
Maximum emission was shown at 535nm.  
 
5.3.2.Standard Curve for AFTD 
A standard curve for AFTD, which was in the same microplate was used to show linearity in 
the concentration range used for the dose-response curve with a R
2
 value of 0.99 (Figure 32).  
This experiment also demonstrated that a sensitivity of 80 is sufficient for the concentration 









Figure 32: Standard curve for AFTD. This assay was conducted at an incubation temperature of 
37C using a BioTek Synergy 4 microplate reader. Data was taken only 2 minutes after 
incubation. Each concentration was buffered to a pH of 7.5 (20mM HEPES, 0.01% tween (v/v)) 
with a sensitivity of 80 and a probe height of 4mm. A correlation coefficient R
2 
value of 0.99 
was determined, indicating a high degree of linearity.    
 
5.3.3.Equilibrium Test for AFTD bound to E6 
In order to gain further information in regards to the equilibrium of our system, change in 
polarization was tested over time using a 25µM concentration of AFTD (Figure 33).  
 
 
Figure 33: Time plot of AFTD and E6 complex. This was conducted at an incubation 
temperature of 37C using a BioTek Synergy 4 microplate reader. Each concentration was 
buffered to a pH of 3.7 (20mM HEPES, 0.01% tween (v/v)). Excitation filter (460/40nm) and 
emission filter (528/20nm) was used and 510nm dichromatic mirror. A sensitivity of 80 was used 
as well as a probe height of 4mm. Our system does not follow any particular pattern however, a 
few time points show great separation. Through this experiment, it was evident that our system 
fluctuates over time. It also shows that the signal from AFTD appears to go down after the two 
hour time point.  For this reason data was to be collected every 15 minutes for a two hour period.  
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5.4.FLUORESCENCE POLARIZATION AND EC50 DETERMINATION 
Fluorescence polarization was used to determine the EC50 value of AFTD, which was 
found to be a positive ligand in the intrinsic Trp fluorescence assay, against E6,. Through this 
assay we hoped to obtain an EC50 for AFTD that was low enough to indicate sufficient affinity 
to E6 for molecular probe. The basic principles of this assay were outlined in section 3.2.3. In 
addition basic principles of dose-response curves, which will be used to estimate the EC50, are 
discussed in section 3.2.4.  
Prior to running the FP curve, calibration experiments (Section 5.3) and preliminary 
attempts (Appendix A) were ran in order to determine concentration ranges and parameters. With 
the information gathered in the calibration experiment, a concentration range for AFTD (1µM-
300µM) was determined. Results indicated that 75 minutes was the best curve (Figure 34). This 
was not against what was shown in the equilibrium experiment (5.3.3) as the system appeared to 
oscillate over the various time periods. However in preliminary attempts time points around the 






Figure 34: FP curve of E6 (0.04mg/ml) incubated with varying the concentration of 3-Amino-5-
Fluorobenzo [E] [1,2,4] Triazine-1,4 Dioxide (AFTD) (1µM-300µM). This experiment was 
performed in a Nunclon® 96 well black bottom plate at an incubation time of 75 minutes, at 
37ºC. The reaction was buffered to a pH of 7.5 (20mM HEPES 7.5, 0. 01% tween). The black 
dotted line represents the background polarization of AFTD without protein. EC50 value was 
estimated at 6µM, which indicates sufficient affinity for a molecular probe.  
 
     The estimated EC50 value from this curve is 6µM with a range of 3.6 µM to 10µM, as 
determined using Prism 6 (Graph Pad, inc)
5
 non-linear regression dose-response four parameters 
function. This range is fairly small and not unreasonable based on previous results (Appendix A). 
The EC50 value is adequate for probe development as molecular probes should have binding 
constants that indicate high affinity. Ideally this value would fall in the nM range; however, µM 
range is deemed sufficient affinity for a molecular probe
6
.  The EC50 value is also aligned with 
the range of affinity generally associated with virtual ligand screening. This experiment validates 
the computational screening, confirming AFTD as a binder to E6 with an EC50 value in the 
micromolar range (6µM).  
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5.5.CELL BASED EXPERIMENTS 
 Cell permeability and toxicity are important factors in the assessment of AFTD as 
potential in-vivo molecular probe for diagnostic imaging.  The cell assays were designed to give 
information regarding specificity of AFTD to E6. The cell types chosen for these assays were 
CaSki, SiHa, and C33A. CaSki and SiHa cell express E6, whereas C33A is a cervical cancer cell 
line that does not express E6.  
5.5.1.Cell viability assay 
      The goal of this experiment is to determine if AFTD is toxic to cells at the concentrations 
proposed (25µM and 10µM), and whether toxicity is E6-dependent. The first cell-based 
experiment used an Axiovert microscope at the Thunder Bay Regional Health Sciences Center 
(TBRHSC) following exposure to two different concentrations of 3-Amino-5-Fluorobenzo 
1,4Triazine Dioxide (10µM and 25uM). Each cell type was incubated for 1, 3, 6, 12 and 24 hours 
then imaged using the microscope. Very little change was noticed after one hour and three hours. 
For this reason the cells were not viewed again until the 24 hour time point. It was discovered 
that all the CaSki and SiHa cells were dead in the 25uM concentration wells, and most of the 
cells were dead in the 10µM wells (Figure 35). To determine whether toxicity was caused by our 
compound and not the ethanol used in our stock solutions, the three cell types were exposed to 
the same concentration by volume of ethanol and incubated for 24hrs as a control in both cell 
lines (Figure 35). Upon observing the cells it was determined that it was not the ethanol killing 




Figure 35: CaSki cells after incubation with AFTD (25uM) for 24hrs. Most of the cells have 
died at this time point: the cells are floating and appear to have a white ring.  
 
 
Figure 36: CaSki cells incubated with ethanol (0.01%) for 24hrs. In this solvent control, the 
cells are indeed healthy as they look normal, indicating that it is AFTD and not ethanol that is 




Since both these cells types contained copies of E6, it was possible that AFTD is killing the 
cells in an E6 specific manner. To further test this hypothesis, an additional cell line C33A was 
tested.  C33A cells were used in order to test if the cell death induced by AFTD is E6-dependent. 
C33A is a cervical cancer cell line, however contains zero copies of E6, making it an ideal 
choice for a negative control. Wells were incubated with AFTD (25µM and 10µM) for 24 hours. 
Ethanol control wells were included in this experiment. Upon examination under a light 
microscope at the 24 hour time point, it was determined that our ligand is generally cytotoxic at 
the concentrations tested (Figure 37). This was further concluded using the ethanol control 
(Figure 38) 
 
Figure 37: C33A cells incubated with ethanol (0.01%). In this solvent control, the cells are 







Figure 38: C33A cell lines after incubation with AFTD (25uM) for 24hrs. Most of the cells are 
dead as they are still attached to the plate. 
 
     Although cytotoxic at 10µM,  AFTD would still be useful as imaging probe in imaging 
modalities such as Position Emission Tomography (PET), where very small amounts, generally 
in the nM range, are used
7
. AFTD can be labelled with 
18
F and it is, hence, suitable as PET 
probe. However, further cytotoxicity studies need to be conducted to investigate if AFTD is safe 
in vivo at lower concentrations. Regardless of toxicology, AFTD may be useful as a biochemical 
probe for fluorescence-based assays involving E6. 
5.5.2. AFTD Cell Permeability Experiment 
In order to determine if AFTD is cell permeable, a fluorescence ligand uptake experiment 
was designed utilizing AFTD’s intrinsic fluorescence. We tested AFTD against the three cell 
types (CaSki, SiHa and C33A) in order to determine if AFTD is cell permeable, and if uptake is 
E6-specific uptake should be seen most in CaSki cells as they contain the most copies of the E6 
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genome, with SiHa and C33A following respectively. All three cell types CaSki, SiHa and C33A 
cells were incubated with two concentrations of AFTD (25µM and 50µM). The time points 
selected were 1, 2, and 3 hours (Figure 39). We also controlled for cell density by reading 
absorbance at 260, 280 and 535nm using the microplate reader. The one hour time point was not 
analyzed as it was inconsistent with the other time points. This is because a lot of air bubbles 
were present in the plates and our technique had to be adjusted for the consecutive time points to 






















Figure 39: Fluorescence intensity (FI) at 2 hour (A) and 3 hour (B) incubation. Intensities 
collected from the second cell permeability test. Cells were incubated AFTD at 25µM and 
50µM. Experiment was conducted in a BioTek Synergy 4 Microplate reader at an incubation 
temperature of 37ºC. AFTD-associated FI showed significant difference (P<0.05) relative to 
control at 50µM in C33A cells, indicating cell permeability. These controls are cells under the 
same environment as those wells that contain cells that have been exposed to AFTD just with no 
AFTD.  Fluorescence was measured using a fluorescence filter system (Ex 460/40nm, Em 
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Multiple comparison ANOVAs were ran for each cell type, time point and concentration. 
The C33A 50µM sample was shown to be statistically higher in fluorescence than its 
corresponding control (Figure 39). This allows us to conclude that our molecule did get inside 
this cell type. This cell type does not contain any copies of E6, however further testing can be 
done outside the scope of the project to look at specificity of binding to E6. The fact that AFTD 
was not present in the CaSki cells does not mean it does not accumulate in this cell type. CaSki 
cells grow in tight clusters making it difficult for compounds to get inside the cells
8
. Another 
potential reason for the negative result could be drug-resistant pumps with affinity for AFTD, 
such as MDR-1, which has been detected in SiHa cells
9
. Drug resistance has been scene in CaSki 
cells although by estrogenic hormones
10
. This hypothesis would need to be further investigated 
using an alternative method, such as a microscope capable of inducing fluorescence. Cells would 
be incubated with different concentration of AFTD (50µM and 25µM) and multiple time points 
would be viewed using the microscopes where pictures would be taken. Pictures would have to 
be taken at time point shorter than one hour to be able to observe drug resistance pumps at play. 
Further experiments are thus needed to determine if AFTD accumulates in the CaSki cell lines 
versus SiHa or C33A.  
5.6.6F4 ANTIBODY COMPETITION ASSAY 
 Preliminary fluorescence polarization assays using AFTD and the 6F4 antibody indicated 
that these molecules bind to different regions within E6. This was evidenced as an increase in 
polarization observed when the antibody 6F4, AFTD, and E6 were all in the same reaction well, 
as shown in appendix A. In order to further demonstrate this cooperative binding event, we 
tested various concentrations of 6F4 antibody against fixed concentrations of both AFTD (6µM) 
and E6 (0.04mg/ml). These correspond to the EC50 concentration conditions as determined in a 
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separate FP assay (Section 5.4). Seven 7 concentrations of 6F4 antibody were tested (4ng/ml to 
0.000004ng/ml). These results are shown in Figure 40. The system appears to be equilibrated 
after 90 minutes. For this reason, the 105min time point was used for further analysis.  
 
 
Figure 40: Time curve showing the change in polarization of the protein and ligand complex and 
the antibody, protein ligand complex. This experiment was run using a fixed concentration of 
ligand 6µM and 0.04mg/ml of protein. This experiment was performed in a Nunclon®® 96 well 
black bottom plate at a temperature of 37ºC and buffered at a pH of 7 (20mM HEPES 7.3, 0.01% 
tween). Our system seems to be equilibrated after 90 minutes. However no real clear pattern of 
change in polarization is observed within the concentrations used of 6F4.  
 
A bar graph was created for the 105 minute time point to compare the FP values for all 
concentration of antibody tested (Figure 41). This bar graph shows the higher concentrations of 
antibody (6F4) do not produce a significant change in polarization when comparing them to the 
positive control of protein E6 and AFTD. The last two concentrations appear to show a 
significant result. One potential explanation of this couple could be that AFTD and antibody 
(6F4) are binding at the higher concentration, which was further investigated.  
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Figure 41: Fluorescence polarization varying the antibody concentration. Seven concentrations 
of 6F4 antibody (4ng/ml-0.000004ng/ml) were used with a constant concentration of AFTD 
(6µM) and E6 protein (0.04mg/ml). This reaction was conducted at an incubation temperature of 
37ºC and at a pH of 7.5 (20mM 7.5 HEPES 0.01% tween (v/v/)). An increase in polarization was 
observed for samples containing 6F4 in presence of AFTD and E6 relative to samples containing 
only AFTD and E6, indicating that 6F4 binds to the AFTD-E6 complex. Some binding between 
the antibody 6F4 and AFTD is also observed.  
 
The fluorescence polarization calculated for AFTD and 6F4 shows some binding 
interaction but with an oscillating behaviour relative to antibody concentration, within the range 
tested (Figure 42). Additional assays are necessary to better understand this behaviour, but 
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Figure 42: Fluorescence polarization versus log of the concentration (µg/ml) of 6F4 antibody. A) 
Concentration scale and B) log scale. Plate was incubated for 105 minutes at a temperature of 
37ºC, and pH was buffered to 7.5 (20mM 7.5 HEPES, 0.01% tween (v/v). Concentrations of 3-
Amino-5-Fluorobenzo [E] [1,2,4] Triazine-1,4 Dioxide (AFTD) at 6µM and E6 protein at 
0.04mg/mLwere held constant while varying the concentration of antibody 6F4.The black dotted 
line represents the polarization of AFTD and E6 and the red dotted line represents the 
background polarization from AFTD on its own. It can be concluded that 6F4 and AFTD are not 





 In order to overcome the inconsistencies shown with the antibody, an additional 
experiment should be performed, where E6 interaction with E6AP, a protein known to bind to 
E6, will be tracked using AFTD. This will give further validation of use of AFTD for the 
purpose of a tool for such biochemical assays.  
Although additional assays need to be performed, the competition assay results indicate 
that AFTD may be useful as a probe for biochemical assays involving E6 interactions with other 
proteins.  E6 is known to interact with many proteins within the cell. The best known interaction 
being with E6AP, which can lead to ubiquitination of p53 if high risk variants are present
11
. E6 is 











 and p300/CBP complex
15
. With these interactions in mind, developing a tool to further 
track protein-protein interaction of E6 would be very useful. Current tools used are GSP-pull 
down assays, which are accurate, however are time consuming and only show interaction inside 
the cell environment
16
. It is important to look at these interactions outside the cell as many 
factors within the cell can impact the interaction of these proteins. Testing E6 protein binding 
interactions outside of the cell would enable a better understanding of these interactions. A 
small-molecule molecular probe to allow for protein-protein interaction to be tracked outside of 
the cell environment would be the first of its kind for E6.  
 
5.7.CHARACTERIZATION OF O-SUCCINYL-L-HOMOSERINE-BODIPY 
      O-succinyl-L-homoserine was conjugated with Bodipy dye (3-Bodipy-
proanoylaminocaproic Acid, N-Hydroxysuccinimide) in order to further validate O-succinyl-L-
homoserine's potential use as a molecular imaging probe. Following successful conjugation of O-
succinyl-L-homoserine, the conjugate was characterized in order to determine what filters and 
mirror were optimal for fluorescence experiments. It was determined, based on emission and 
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excitation analysis, that the conjugate compound has well-defined maximum excitation (500nm) 
and maximum emission (510nm) (Figure 43). Given these values, an excitation filter (485/20nm) 
and emission filter (528/20nm), and a dichromatic mirror (510nm) were selected.     
 
Figure 43: Emission (green) and excitation (red) plot of O-succinyl-L-homoserine-BODIPY. 
This plot shows a maximum excitation at 500nm and emission at 510nm. Using these values we 
were able to develop a proper optical system (Ex filter: 485/20nm, Em filter: 528/20nm, and 
dichromatic mirror 510nm)  
 
       Prior to conducting this experiment a standard curve was run using all the concentration 
proposed for the actual experiment to make sure that our concentrations demonstrated linearity 
(Figure 44). It was determined that this filter set up was adequate as an R
2 
value of 0.90 was 
determined indicated linearity (Figure 44).    
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Figure 44: Linear fluorescence intensity plot of O-succinyl-L-homoserine-BODIPY (300M, 
100M, 10M, and 1M) and protein E6 (0.04mg/ml). Plate was incubated at a temperature of 
37C and pH was buffered to 7.5 (20mM HEPES, 0.01% tween (v/v)).R
2
 was determined using a 
linear function to be 0.90.  
   
5.8. FP FOR O-SUCCINYL-L-HOMOSERINE CONJUGATE 
 Fluorescence polarization was conducted using three concentration of O-succinyl-L-
homoserine-BODIPY (100M, 10M, and 1M) and 0.04mg/ml of E6 (Figure 45).  
 
Figure 45: Fluorescence polarization time plot of O-succinyl-L-homoserine-BODIPY (100M, 
10M, and 1M) and protein E6 (0.04mg/ml). Plate was incubated at a temperature of 37C and 
pH was buffered to 7.5 (20mM HEPES, 0.01% tween (v/v).  Protein concentration was held 
constant at 0.04mg/ml. The dotted line represents the baseline polarization of O-succinyl-L-
homoserine-BODIPY. Equilibrium is reached around 1hour, but FP values are at baseline by 
then. Our results indicate that the O-succinyl-L-homoserine-BODIPY is not binding at any 
concentrations tested. 



























Based on the time plots (Figure 45), it is evident that the system equilibrated after 1hour. 
Upon equilibrium there is no difference in polarization between free O-succinyl-L-homoserine-
BODIPY and O-succinyl-L-homoserine-BOPIDY added to E6 protein at any of the 
concentrations tested.  
 
Figure 46: Bar graph of polarization (mP) at 60 minutes for the O-succinyl-BODIPY binding 
experiment. Plate was incubated at a temperature of 37C and pH was buffered to 7.5 (20mM 
HEPES, 0.01% tween (v/v). E6 protein concentration was held constant at 0.04mg/ml. All three 
concentration were plotted (100µM, 10µM and 1µM) with the control in red, which represents 
the polarization (mP) of  O-succinyl-L-homoserine-BODIPY on its own. This bar graph 
demonstrates that O-succinyl-L-homoserine-BODIPY does not bind to E6 at the concentrations 
tested.  
 
Based on these results it is not believed that O-succinyl-L-homoserine-BODIPY binds to E6. 
However, results for unlabeled O-succinyl-L-homoserine are still potentially promising, as 
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Chapter 6.Conclusion and Future Work 
Much work has gone into further understanding HPV as it remains a large concern in 
today’s health care system, due to its association with various cancers, including cervical. HPV 
remains a complex virus with many known genotypes. However, the complexity does not end 
there as even high risk types do not necessarily express variants of E6 responsible for the cell 
immortalization leading to increased susceptibility to cancer development. Finding a way to 
detect protein E6, specifically those variants associated with invasive cancer, has the potential to 
aid in early intervention, thus improving the life of those impacted. Finding a molecule that can 
be used as a molecular probe for biochemical assays for E6 protein-protein interactions (PPIs) 
would also be beneficial as E6 is known to bind to many proteins within the cell. To date no 
method for probing PPIs outside of the cell environment has been developed. This would allow 
for better understanding of these interactions, and may lead to new therapeutic and diagnostic 
strategies.    
To date there is not a small organic molecule known to bind specifically to E6. This left a 
great starting point in the pursuit to find such a compound. Through using a combination of 
computational methods and experimental methods our hope was to find a small organic molecule 
that could bind to wild-type HPV variant 16 protein E6 specifically. Such small organic 
molecule could be a very useful tool in the further understanding of HPV infection. 
3-Amino-5-Fluorobenzo [E] [1,2,4] Triazine-1,4 Dioxide (AFTD), showed great promise 
and for this reason was tested extensively, both computationally and experimentally. Due to its 
intrinsic fluorescence, and fluorine atom this molecule could be used for optical imaging or 
Positron Emission Tomography (PET), respectively, if shown to be specific and non-toxic.  
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 Both tryptophan and fluorescence polarization assays for AFTD against E6 were 
conclusive of a concentration-dependent binding. An EC50 value of 6µM was determined for 
AFTD and this is deemed sufficient for molecular probe development. This not only 
demonstrates affinity but also indicates that binding is indeed specific. Cell based assays 
indicated that AFTD is cytotoxic at 25μM; however further cytotoxicity experiments would need 
to be conducted to test at what concentration AFTD could potentially be used safely in-vivo. Cell 
based experiments also demonstrated evidence of cell permeability; however this was shown 
significantly in a cell line that contains no copies of E6 (C33A). This event was believed to be 
the result of drug resistance pumps shown and documented in SiHa cells, and morphological 
characteristics documented and shown in CaSki cells. Microscopic images along with shorter 
time points will allow us to validate this hypothesis. High Intensity Focused Ultrasound (HIFU) 
methods could be employed in order to overcome the tightly packed clusters that limit 
permeability, shown and documented in CaSki cells.  
AFTD also appears suitable for usage as a molecular probe for a biochemical protein-
protein interaction assay. AFTD was able generate results that indicate protein-protein 
interactions between E6 and HPV16 E6 specific antibody (6F4). However, due to inconsistencies 
seen with this antibody other proteins known to bind to E6, will be tested in the future such as E6 
Associated Protein (E6AP).    
In addition to AFTD, O-succinyl-L-homoserine, and paclitaxel also demonstrated binding 
to E6 when using intrinsic tryptophan fluorescence and could be further investigated. O-
succinyl-L-homoserine conjugated to a bodipy dye failed to bind to E6, which is disappointing. 
Conjugation with other dyes could be explored, both computationally and experimentally in an 
attempt to find a conjugate that retains binding affinity to E6.  Paclitaxel showed an excellent 
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dose-dependence at the concentrations tested using intrinsic tryptophan fluorescence. This is a 
particularity interesting result as Paclitaxel is a commonly used chemotherapy drug. However, in 
order to fully characterize Paclitaxel, additional experimental testing would be required in order 
to gain an accurate EC50. Due to availability of radio-labelled Paclitaxel this could be easily 
done using a scintillation proximity assay. Paclitaxel would be an interesting probe for E6 due to 
its current use and availability within a clinical setting. Paclitaxel it is already a characterized 
drug approved for clinical use.  
Computational screening conducted using the structure of the N-terminal domain of E6 
suggests additional compounds that could be characterized in the future as potential molecular 
probes. Also with the publishing of a full structure of HPV16 E6 (PDB 3GIZ) further 
computational studies can be conducted with the already created databases. This will allow us to 
further validate our computational work with the two separate domains.   
Through the utilization of a variety of computational and experimental techniques we 
were able to find and begin the characterization of AFTD. Affinity was demonstrated both 
computationally and experimentally. Cell permeability was also demonstrated in C33A, however 
due to potential drug resistance shown in CaSki and SiHa cells further work will need to be 
conducted in order to determine specificity for E6. AFTD is also believed to be a suitable probe 
for biochemical assays for E6 protein-protein interactions. Other molecules such as O-succinyl-
L-homoserine and paclitaxel also showed great promise for use as a molecular probe. However, 
AFTD due to advantageous characteristics was the major focus of this study. We believe that 
AFTD as a dual propose molecular probe could be a very powerful tool in furthering our 
understanding of HPV's link to cancer.  The same approach that identified AFTD may lead to the 
 
100 






Chapter 7.Appendix A: Calibration and Preliminary Results 
7.1.OBTAINING FLUORESCENCE AND ABSORBANCE SPECTRUMS FOR 
LIGANDS   
 Prior to running ligand binding assays aborbance and emission spectrums were run for 
each ligand. Emission spectrums were run at an excitation of 288nm in order to make sure 
ligands that could cause quenching in tryptophan fluorescence were identified. Absorbance 
spectra for all four ligands were obtained using a Take3 microplate. Fluorescence emission 
spectrum of all for ligands was obtained using a Nunclon® 96 well- microplate. Both plates were 
run on a Synergy 4 BioTek microplate reader at an incubation temperature of 37C. All ligands 






















Figure A: Shows the emission (A) absorbance (B) and for the four ligands tested (10M). These 
graphs were taken using a Nunclon® 96 well plate incubated at 37C at a constant pH using a 
HEPES 7.0 buffer system (20mM Hepes pH 7.3). These ligands were excited at 288nm (B) and 
the blank containing the buffer and water. Each well was toped up to a total volume of 100L. 
Each ligand was at a concentration of 10M. From these graphs we can see that Aminopterin is 
the only ligand that may cause quenching in tryptophan fluorescence assays. In addition a 
maximum absorbance was identified at 270nm with a secondary max at 470nm for AFTD with a 




  Ir was determined that the only ligands that were fluorescently active were Aminopterin 
and AFTD. AFTD was determined to have a max absorbance at 270nm and a max emission at 
535nm. Since this compound was to be used in fluorescence polarization assays a proper filter 
set would need to be established. Due to availability of filters the secondary absorbance 
maximum was used (470nm) (Figure A). From this a filter set containing an excitation filter 
(485/20nm), emission filter (528/20nm), and dichromatic mirror (510nm) was implemented. 
Paclitaxel appeared to come out of solution and for this reason was not included in the 
absorbance spectrum .  
7.2.PRELIMINARY RESULTS   
7.2.1.6F4 antibody preliminary test to select concentration  
Lots of work has been conducted with an antibody specific to E6 (6F4), as it has taken 
part in both tryptophan fluorescence, and fluorescence polarization experiments.   
Preliminary experiments were conducted to determine the proper concentration of 
antibody to be used in tryptophan fluorescence assays. Four 100 fold dilutions of the antibody 
from a 4µg/mL stock solution were prepared.  Change in intrinsic tryptophan fluorescence 
induced on E6 in presence of the antibody was measured. Results indicated that a change of at 
least 30% was possible with each of the concentrations used (Figure B). However the 0.04ng/mL 





Figure B: %change curves showing the change in intrinsic tryptophan fluorescence of the protein 
and ligand complex and the antibody, protein ligand complex. A)5minutes B) 30minutes and C) 
1hour. This experiment was run for 60 minutes using 4g/mL, 4ng/mL, 0.4ng/mL, 4pg/mL, 
0.04pg/mL of antibody, 10M of ligand, and 0.24M of protein. This experiment was performed 
in a Nunclon® 96 well black bottom plate at a temperature of 37C and buffered at a pH of 7 
(20mM HEPES 7.3, 0.01% tween). From this we can see that all the concentrations of antibody 
produce about the same change in tryptophan florescence. From this we selected a concentration 




In order to assess whether or not the antibody contains tryptophan curves of each 
concentration were examined with an excitation of 288nm (Figure C). As shown in figure C, the 
6F4 antibody contains tryptophan and proper controls for its contribution to the measurements 
need to be used in other tryptophan fluorescence assays for each concentration tested.  
  
Figure C: Fluorescence intensity curve of the antibody (6F4) at various concentrations on its 
own. This experiment was run and data was taken at 60 minutes using 4g/mL, 0.04µg/mL, 
0.0004ng/mL, 0.000004µg/mL, 0.00000004µg/mL of antibody, 10M of antibody, and 0.24M 
of protein. This experiment was performed in a Nunclon® 96 well black bottom plate at a 
temperature of 37ºC and buffered at a pH of 7 (20mM HEPES 7.3, 0.01% tween). It is shown 
based on the fluorescence intensity in the 300nm-400nm that tryptophan’s are present in the 
antibody (6F4).  
 
7.2.2.Fluorescense polarization using AFTD and antibody 6F4  
In order to further investigate AFTD binding to E6, 6F4 antibody was tested in 
fluorescence polarization competition assays (Figure D).  A competitor would decrease the 
polarization associated to ligand binding to E6, as it would displace the ligand from the binding 
site. It was observed in this assay that at 60min, and 15min that the polarization actually 
increased (Figure D).  This was an interesting result as polarization is proportional to the 




the antibody, AFTD and E6 would be higher than the AFTD complex values.  This increase in 
polarization indicates that both antibody (6F4) and AFTD are bound at the same time. This 
property could be used to track protein-protein interactions involving E6. The results obtained 
for the 6F4 antibody show that AFTD is a good candidate for the development of a fluorescence-
based assay to study protein-protein interactions involving E6.  
   
Figure D: Time curve showing the change in polarization of the protein and ligand complex and 
the antibody, protein ligand complex. This experiment was run for 60 minutes using 0.4ng/mL of 
antibody, 100M of ligand, and 0.90M of protein. This experiment was performed in a 
Nunclon® 96 well black bottom plate at a temperature of 37C and buffered at a pH of 7 (20mM 
HEPES 7.3, 0.01% tween). This graph demonstrates the increase in polarization at 15minutes 
and 60minutes when the antibody (6F4) is present. This increase in polarization indicates a 
complex between AFTD, 6F4, and E6.   
 
This result is in agreement with the modeling results, as the E6 specific antibody is 
known to bind the N-terminus, whereas the docking results suggest that AFTD binds to the C-
terminus domain of E6. Further concentrations of the antibody and of AFTD need to be tested in 
order to better characterize the complexes. From this assay we can conclude that there is some 




further validated by attempting a dose response curve varying the concentration of 6F4 (section 
5.5).  
7.2.3.Tryptophan Fluorescence Results  
 Prior to obtaining these results four previous attempts were made. These results were all 
inconclusive due to lack of solvent controls and concentration of protein. In addition, the error 
between wells was extremely high in some cases.  This was attempted prior to obtaining accurate 
results (section 5.2). 
7.2.3. a)First attempt  
Tryptophan fluorescence was initially conducted using a fixed concentration of both 
protein (0.01mg/mL) and ligand (10µM). Error was extremely high so error bars were not 
plotted, in order to make graphs easier to read. For this reason this plot was not included.  
7.2.3. b)Second attempt,  
The protein concentration was slightly increased from 0.01mg/mL to 0.02mg/mL. It was 
noted that the error between wells was significantly lower than in the first attempt. It was 
concluded that mechanical issues were partly to blame for the inconsistencies in the first attempt. 
Some parameters were adjusted in order to reduce error, such as the number of reads per well. 
The default number of scans is 10. We changed this value to 20 scans per well. The samples 
were run in triplicate instead of duplicate, which also aids in lowering the error. Only one ligand 
showed (O-succinyl-L-homoserine) a significant change (> 30%) in the protein's intrinsic 
tryptophan fluorescence (figure 5A). O-succinyl-L-homoserine also showed an increase in time 






Figure E: Percent change in protein intrinsic tryptophan fluorescence upon ligand interaction. 
Experiment (A) 30minutes and (B) 1hour. The concentration of E6 was 0.02mg/mL for all 
samples. Each ligand was tested at10M. This experiment was performed in a Nunclon® 96 well 
black bottom plate at a temperature of 37˚C and buffered at pH of 7.3 (20mM HEPES 7.3, 0.01% 
tween (v/v)). The change in tryptophan fluorescence was monitored over time and the percentage 
change relative to E6 without ligand was plotted using prism graph pad. At 1 hour incubation, O-
succinyl-L-homoserine induces a 42.9%. Increase in Trp fluorescence. The dotted line represents 




Some of the other ligands such as 3-Amino-5-Fluorobenzo [E] [1,2,4] Triazine-1,4 
Dioxide (AFTD) and Aminopterin showed a decrease in change in intrinsic tryptophan 
fluorescence at 30mintues versus 1 hour. Paclitaxel did not cause significant change in intrinsic 
Trp fluorescence, appearing not to bind, and its error bars were very high, which is why they 
were not included in the plot (Figure E).  
7.2.3. c)Third attempt  
The last experiment described appeared successful, however we did not control for 
solvent effects. O-succinyl-L-homoserine was dissolved in water so proper controls for this 
ligand were already in place. Other ligands such as 3-Amino-5-Fluorobenzo [E] [1,2,4] Triazine 
1, 4- Dioxide (Fluoro), were dissolved in a half water/half ethanol solution. In addition, 
paclitaxel and aminopterin, were dissolved in 100% DMSO. Since solvent can have impact on 
fluorescence and potentially the environment of tryptophan, we repeated this experiment a third 
time to include solvent controls. A positive control was also added (Monoclonal antibody 6F4).  
This antibody was previously tested (Section 7.2.1), and shown to induce a significant change in 
intrinsic tryptophan fluorescence relative to the unbound protein. Since the previous experiments 
were positive for some of the ligands, we tested different concentrations of each ligand 
(25,10,and 1M). In theory, the change in tryptophan fluorescence should be proportional to the 
concentration of the ligand. Unfortunately this experiment was unsuccessful for the 
concentrations tested, with no significant change in intrinsic fluorescence for any of the ligands 







Figure F: Intrinsic Trp fluorescence. Protein, antibody (ligand) and antibody protein complex. 
Assay was run in a Nunclon® 96 well microplate in a BioTek Synergy 4 microplate reader. 
Samples were incubated at a temperature of 37C and buffered to a pH of 7.3 (20mM HEPES 
7.3, 0.01% tween (v/v).  Protein was at a concentration of  0.01 mg/mL and the antibody was at a 
concentration of 0.04g/mL. Emission was collected at 350nm with an excitation wavelength of 
288nm. No evidence of the antibody binding to the protein is observed, even though the antibody 
is E6-specific. This is believed to be in large part to the low concentration of the protein used.  
 
It was concluded that the protein concentration used was too low to conduct tryptophan 
fluorescence. No significant change in intrinsic Trp fluorescence were seen associated to any of 
the ligands tested (Paclitaxel, Aminopterin, AFTD, and O-succinyl-L-homoserine). Comparing 
this result to our first tryptophan fluorescence attempt this experiment confirmed that a protein 




7.2.3. d)Fourth attempt  
The tryptophan fluorescence experiment was repeated using a higher concentration of 
protein (0.02mg/mL) under the same conditions as the previous experiment. Antibody 6F4 
appeared to be below the 30% threshold in this experiment, which indicates experimental issues. 
O-succinyl-L-homoserine appears to be a positive result, however does not show dose 






Figure G: Bar graph of change in E6's intrinsic tryptophan fluorescence experiment A) 30min B) 
1hour. Change is shown at 30min (A) and 1hour (B) incubation times. Assay was run using 
Nunclon® 96 well microplate in a BioTek Synergy 4 microplate reader. Samples were incubated 
at a temperature of 37C and buffered to a pH of 7.3 (20mM HEPES 7.3, 0.01% tween (v/v).  
Protein was at a concentration of 0.02mg/mL and the antibody was at a concentration of 
0.04g/mL. Ligands were tested at 25M, 10M, and 1M. Emission was collected at 350nm 
with an excitation wavelength of 288nm. The dotted line represents the 30% change in intrinsic 
fluorescence which is considered to be significant and associated to binding. The change in Trp 
fluorescence is dose-dependence for 3-Amino-5-Fluorobenzo [E] [1,2,4] Triazine-1,4 Dioxide 





In this case the best result was AFTD (figure G). Dose dependence was shown for this 
ligand at the concentrations used in this assay. The 10µM and 1µM appeared to show dose 
dependence for Paclitaxel, however the 25uM concentration due to high error was inconclusive 
(Figure G). This high error is most likely associated with paclitaxel precipitating out of solution 
at high concentration as it requires a high concentration of DMSO to stay in solution. One 
interesting result from this assay was that the antibody (6F4), which was previously shown to be 
positive, was negative. In this experiment the result was closer to 20% at best. One possible 
reason for this inconsistent result is due to improper storage of the antibody. This antibody had 
been stored in a minus 20ºC freezer for a number of months and had been warmed to room 
temperature and refrozen a number of times. It is believed that this sample of our antibody was 
most likely denatured. Desmosine was added as a negative control, however appeared to be 
positive. When examining the computational results again this was not a surprise as Desmosine 
was still above our Binding Energy mean.  O-succinyl-L-homoserine is not showing dose 
dependence. However the positive result at 10µM is consistent with previous experiments.  
7.2.4.Fluorescence Polarization Results  
7.2.4. a)Preliminary polarization assessment  
Prior to attempting a dose response curve we need identify a concentration of fluorescent 
compound to use, and perhaps gain some hints as to potential concentration ranges we can use. 
The concentrations of florescent compound used were 10nM, 100nM, 10M, and 100M 
(Figure H).  Each concentration was tested against various concentration of protein (Figure H). It 
was evident that the lower concentrations (10nM and 100nM) were not able to produce a 






Figure H: Fluorescence polarization assay at 10µM and 100 M of 3-Amino-5-Fluorobenzo [E] 
[1,2,4] Triazine-1,4 Dioxide (AFTD) with varying the concentration of E6 (0.18µM, 0.09µM, 
0.05µM, and 0.009µM) . Reaction was buffered at pH of 7 (20mM HEPES 7.3, 0.01% tween) 
and incubated at a temperature of 37C for one hour. Excitation filter (485/12) and emission filter 
(528/12) were used to measure fluorescence intensity in the parallel and perpendicular directions. 
The 100µM ligand concentration produces a cleaner signal with less standard error.  
 
7.2.4. b)First dose-response curve attempt 100µM AFTD  
A dose response curve for AFTD was first attempted using a fixed concentration of the 
compound (100M). Initially results were poor and little to no convergence was found. This lead 
to adjusting the probe height to 4mm, to better suit the total volume of 100µL. Using the  
adjusted probe height, a better curve was obtained at the three-hour time point (Figure I). From 
this graph we were able to use non-linear regression dose-response fitting four parameter was 
implemented in Prism (GraphPad, Inc.) to estimate EC50 (0.7µM) (Figure I), however this was 





Figure I: Dose-response curve at 3 hour incubation using 100M of 3-Amino-5-Fluorobenzo [E] 
[1,2,4] Triazine-1,4 Dioxide (AFTD) at varying protein (E6) concentrations (0.0010µM -1.8µM). 
Probe height was 4mm and a sensitivity of 50 was used. This experiment was performed in a 
Nunclon® 96 well black bottom plate at a temperature of 37ºC and buffered at a pH of 7 (20mM 
HEPES 7.3, 0. 01% tween). Excitation filter (485/12) and emission filter (528/12) were used to 
measure fluorescence intensity in the parallel and perpendicular directions. The top part of the 
curve is not well defined. Therefore greater concentrations of protein are required. An EC50 
value of 0.7µM was estimated using Prism Graph non-linear regression four parameter equation.  
 
Since the top part of the curve is not complete this EC50 value is merely an estimate. 
Other time points to show that the system is equilibrated could not be analyzed as the probe 
height was not properly adjusted until the three hour time point. With this in mind, the 
experiment was repeated a second time with higher concentrations of protein. In addition, the 
concentrations were chosen to better space the points as the first curve had most points too close 
together (Figure I).        
7.2.4. c)Dose-response curve evaluation 25µM and 50µM AFTD 
A preliminary fluorescence polarization test was conducted at 25uM and 50uM to 




response curve. Values in this experiment were collected every 15 minutes and it was determined 
that our system equilibrates around 45min-60min incubation time. The 50uM curve at one hour 
(figure 10A) produced an adequate signal to noise ratio, however the shape of the dose-response 
curve was not ideal as the concentrations of AFTD used were not sufficient to produce a 
significant polarization signal (Figure J). The 25µM curve (Figure J) also produced good signal 
to noise ratio with a more satisfactory curve (Figure J).  
 
Figure J: 1 hour does response attempt using 25µM and 50µM of AFTD. Various concentrations 
of E6 protein were used (0.007mg/mL -0.07mg/mL). This experiment was performed in a 
Nunclon® 96 well black bottom plate at a temperature of 37C and buffered at a pH of 
7.3(20mM HEPES 7.3, 0. 01% tween). From this plot it is evident that the shape of the 25µM is 
much better than the 50µM curve. 25µM curve had an EC50 value of 0.04mg/mL where the 
50µM curve had an EC50 values of 0.25mg/mL.  
 
An EC50 value of 0.04mg/mL was estimated for the 25µM curve using the non-linear 
regression dose-response four parameter function. It was concluded that a ligand concentration 




7.2.4. d)Full 25µM Dose-response attempt  
With the information gathered above, a new dose response curve was obtained at 25µM 
of 3-amino-5-fluorobenzo [e] [1,2,4] triazine 1, 4 dioxide. The protein concentrations varied 
from 0.09-1.07M (Figure K).  
            
Figure K: One hour does response attempt using 25µM AFTD. Various concentrations of E6 
protein were used (0.007mg/mL -0.07mg/mL). This experiment was performed in a Nunclon® 
96 well black bottom plate at a temperature of 37C and buffered at a pH of 7.3 (20mM HEPES 
7.3, 0. 01% tween) at fixed concentration of AFTD 25µM.  Unfortunately this curve did not 
converge and it was determined that a different approach would need to be taken in order to 
obtain a good quality dose-response curve.  
 
The curve obtained was of poor quality and could not be used to estimate EC50 with confidence. 
Our concentrations were noticeably too close in log units and the top part of the curve is not 
well-defined. The best time point curve was observed after 45minutes (figure K).  Since a good-
quality dose-response curve could not be obtained varying the concentration of the protein, a 




7.2.4. e)Dose-response curve varying AFTD concentration   
Based on the equilibrium analysis, it was determined that data would be collected every 
15 minutes after 30 minutes until the 75 minute mark. Another important test was to determine 
the proper sensitivity setting to use. This sensitivity needs to be high enough to give us a 
reproducible signal for our lowest concentration and not so high that it over flows our highest 
concentration. Through testing a few sensitivities, it was determined that a sensitivity of 100 was 
appropriate for the proposed concentration range of 3-Amino-5-Fluorobenzo-1,4-Triazine 
Dioxide (300µM-1µM).   
 Using the preliminary work a dose-response curve was obtained with variable ligand 
concentration, using the parameters determined in the preliminary experiments. Numbers right 
from the first time point at 30minutes appeared to be off. One big concern was that the 
perpendicular values appeared to be higher than the parallel values. Data was collected up to the 
one hour mark. The remainder of the scans collected were done using a slightly different 
protocol, however this appeared to not fix the problem. Once experiment was completed, data 
was still analyzed in order to determine what the issue was. Upon further investigation, it was 
determined that our protein sample was contaminated. This was evident as the protein alone well 
had a high fluorescence intensity value. Upon analysis it was determined that it was 
contamination from the ethanol solution used to create the protein blank. Despite this, data 
analysis was conducted by discounting the fluorescence in the protein alone well in both 
directions. In addition, our lower concentration (1µM) did not produce a signal strong enough to 






Figure L: 30minute does response attempt using 0.04mg/mL of E6 protein and varying the 
concentration of 3-Amino-5-Fluorobenzo [E] [1,2,4] Triazine-1,4 Dioxide (AFTD) (1µM-
300µM).  Probe height was 4mm and a sensitivity of 100 was used. This experiment was 
performed in a Nunclon® 96 well black bottom plate at a temperature of 37C and buffered at a 
pH of 7.3 (20mM HEPES 7.3, 0. 01% tween). Red line represents the background polarization of 
3-Amino-5-Fluorobenzo [E] [1,2,4] Triazine-1,4 Dioxide (AFTD) on its own. EC50 value was 
estimated at 16.5µM.  
 
The 30minute time point converged and generated an EC50 value of 16.5 µM. This value 
is close to our expected value. However due to contamination from the ethanol solution used this 
curve was not able to be trusted.      
7.2.5.Preliminary Ligand Uptake Experiment  
Cell permeability needs to be tested. Since our molecule is intrinsically fluorescent this 
can be used to trace if the molecule is getting inside the cell. CaSki, SiHa, and C33A cell types 
were used for cell permeability assays at 10uM and 25uM of AFTD. Ethanol control wells were 
present for each cell type and concentration. The cells were incubated at various time points (1, 
3, and 6 hours), lysed and filtered with a 0.2 micron filter. Each well was kept as an individual 




the concentration of our molecule within the cell. Each sample from each time point was then 
plated (100µM) and read in the Microplate reading using an excitation of 270nm and emission at 























Figure M: Fluorescence intensity at 1 hour (A) and 3 hour (B) incubation of  3-Amino-5-
Fluorobenzo [E] [1,2,4] Triazine-1,4 Dioxide (AFTD) at 10µM and 25µM with CaSki, SiHa, and 
C33A cell lines. Intensities collected from the first cell permeability test. Cells were lysed after 
incubation and filtered with 0.2 micron filter. 100µM of each sample were analyzed with an 
excitation of 270 nm, and emission at 525 nm in a Biotek Synergy 4 microplate reader. Values 
were blank-discounted.  Samples were compared to their corresponding controls which account 
for cellular background fluorescence. Some evidence of cell permeability was obtained in 
particular in the C33A cells. However, this experiment needs to be repeated to show 





The most significant differences between samples and controls were observed for the C33A 
cells. Some difference was also present in the SiHa cells; however the background control 
appeared to be higher than the sample after three hours. Some of these inconsistencies could be 
due the use of a monochromator instead of optical filters for the readings. Also, the readings 
were not normalized for cell density. It is assumed that the same number of cells in each well is 
the same, however this was not determined and many factors may alter cell growth and 
proliferation differently across samples. In addition by the time the fluorescence was read the 
cells had been sitting in DMSO for over 48hours. Since DMSO is a harsh solvent it could cause 
degradation of many components contributing to the fluorescence readings. The experiment was 









Chapter 8.Appendix B: Supplementary Material 
















































Parameters Used for MMFF94x Energy Minimization of E6 and ligand Databases 
Gradient 0.05    
Options: Calculate Forcefeild Partial Changes   
The remaining boxes were unchecked.   
Enable: bonded, van der Waals, Electrostatics, Restraints, and cutoff     
Solvation: Distance     
Scale Like: 1  




Off: 10  
Dielectrin: 1  
Exterior:80  
Unlike: 0  
Wild: 1   
Treads: 0  
 
Table A: Compounds that passed the R1 threshold with structures  
Rank Identifier Binding Score 
(kcal/mol) 
IUPAC name Molecular 
Structure  






























Table B: Compounds that passed R2 threshold with structures  
Rank Identifier  Binding Score 
(kcal/mol) 











































































































































Molecular Structure  


















Table D: Top 5 compounds from the fluorine-containing molecule database in order of rank with 























































































1,4 Dioxide  
12 -49.53 AFTD 
 
Aminopterin 8 -59.61 Amino 
 
Paclitaxel 4 -70.10 Pac 
 
 
